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ABSTRACT: The Mediator complex-associated cyclin-de-
pendent kinase CDK8 has been implicated in human disease,
particularly in colorectal cancer where it has been reported as a
putative oncogene. Here we report the discovery of 109
(CCT251921), a potent, selective, and orally bioavailable
inhibitor of CDK8 with equipotent affinity for CDK19. We
describe a structure-based design approach leading to the
discovery of a 3,4,5-trisubstituted-2-aminopyridine series and
present the application of physicochemical property analyses
to successfully reduce in vivo metabolic clearance, minimize
transporter-mediated biliary elimination while maintaining
acceptable aqueous solubility. Compound 109 affords the
optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to
animal models of cancer.
■ INTRODUCTION
The Mediator complex is a multiprotein assembly comprising
at least 30 subunits that functions as a regulator of gene
transcription in multiple contexts including stem cell function,
the immune response, inflammation, cell adhesion, the
epithelial to mesenchymal transition and development.1−5
The Mediator complex-associated kinase CDK8 and its paralog
CDK19 are cyclin C-dependent enzymes that, along with
MED12 and MED13, form the kinase module of the Mediator
complex.6,7 CDK8 has been reported to regulate basal
transcription by phosphorylation of RNA polymerase II8 and
to phosphorylate E2F1, thereby activating WNT signaling.9
Interestingly, CDK8 gene expression correlates with activation
of β-catenin, a core transcriptional regulator of canonical WNT
signaling, in colon and gastric cancers.10,11 CDK8 gene
expression also correlates with increased mortality in colorectal,
breast, and ovarian cancers;12 furthermore CDK8 is overex-
pressed and essential for cell proliferation in melanoma.13
Consistent with these reports, CDK8 is located in a region of
chromosome 13 known to undergo copy number gain in ∼60%
of colorectal cancers and inducible shRNA-mediated knock-
down of CDK8 protein reduces the growth of HT29 and
Colo205 colorectal cancer human tumor xenograft animal
models harboring CDK8 gene amplification.14 Notably, CDK8
expression transforms NIH3T3 cells into a malignant
phenotype whereas a kinase-dead mutant does not, thereby
implicating the kinase function of CDK8 in oncogenesis.15 The
function and role of CDK19 are less well explored. CDK19 has
been reported to form Mediator complexes independent of
CDK8; however their context-dependent roles are the subject
of ongoing study.7
Previously reported small molecule ligands for CDK8 and its
paralog CDK19 have been described in a recent comprehensive
review.16 In brief, the steroidal natural product cortistatin A (1)
was the first-reported high affinity and selective ligand for
CDK8/19 (Chart 1);17 recent disclosures include a patent
describing cortistatin A analogs and a report demonstrating
potent in vitro and in vivo antileukemic activity of cortistatin A
through dual CDK8/19 inhibition.18,19 The marketed kinase
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inhibitor sorafenib (2) has been cocrystallized with CDK8/
cyclin C,20 and subsequently the same group reported a
fragment-based approach to CDK8 ligands building from the
urea moiety associated with the type II binding mode of
sorafenib.21 Type II kinase inhibitors linifanib (3) and
ponatinib (4) have also been reported to bind both CDK8
and CDK19.22 Recently, a cell-based HTS campaign seeking
inhibitors of p21-activated transcription was reported; this
effort led to the discovery of aminoquinazoline-based CDK8/
19 ligands, exemplified by senexin B (5) (Chart 1).23 Other
series of small molecule CDK8 inhibitors have also been
reported in the patent literature.24−26
We have previously reported the discovery of 6
(CCT251545), a potent, orally bioavailable small molecule
inhibitor of WNT signaling from a cell-based pathway screen
(Chart 1).27 We identified protein kinases CDK8 and CDK19
as the primary targets of this trisubstituted pyridine series and
demonstrated a strong correlation between CDK8 and CDK19
binding affinities in this chemical series.22 Here we describe the
medicinal chemistry optimization of 6 to compound 109, a
potent, selective, and orally bioavailable inhibitor of CDK8 with
equipotent affinity for CDK19 that demonstrates potent cell-
based activity together with improved pharmacokinetic and
pharmaceutical properties. We demonstrate inhibition of CDK8
Chart 1. Small Molecule CDK8/19 Ligands: Cortistatin A (1), Sorafenib (2), Linifanib (3), Ponatinib (4), Senexin B (5), and 6
Scheme 1. General Synthetic Routes to 3,4,5-Trisubtituted Pyridinesa
aThe asterisk (∗) indicates different solvent and/or slightly different conditions were used for compounds 17, 18, 42, 47, 50, and 52.
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function concomitant with reduced proliferation in a human
tumor xenograft animal model of colorectal cancer.
■ CHEMISTRY
The general synthetic method for the preparation of 3-Cl and
3-F substituted pyridine analogues involved initial SNAr
displacement at the 4-position of 3-bromo-4,5-dichloropyridine
(7) or 3-bromo-4-chloro-5-fluoropyridine (57) to give
intermediates 8, 26−36, 58, 59, and 96, which were then
subject to Suzuki cross-coupling to give final compounds 17−
25, 40−56, 60−63, and 100−105 (Scheme 1 and Tables 2, 3,
4, and 7). The corresponding CF3-substituted pyridines (70,
71, and 72, Table 4) were synthesized by two alternative routes.
Compound 71 was prepared by selective copper-mediated
trifluoromethylation at the bromo-substituted carbon atom of
8,28 followed by Suzuki coupling at the pyridine chloro
substituent. Alternatively, compounds 70 and 72 were prepared
by SNAr displacement at the 4-position of 3,5-diiodo-4-
chloropyridine 64, followed by copper-mediated trifluorome-
thylation at one iodo-substituted carbon followed by Suzuki
cross-coupling at the other.
2-Aminopyridines (88, 92−95, 108, and 111, Tables 5 and
8) were prepared by SNAr-mediated displacement of the 4-
chloro substituent in pyridines 73, 74, and 75 followed by
Suzuki cross-coupling (Scheme 2). In the case of 85−87, 89−
91, 109, and 110, we found that protection of the primary
amine with a PMB group improved both the SNAr displacement
and the subsequent palladium-mediated cross-coupling reac-
tion; deprotection was achieved using trifluoroacetic acid at
room temperature.
■ RESULTS AND DISCUSSION
Compound 6 is a high affinity ligand for CDK8 and CDK19
(IC50 of 7.2 ± 1.4 and 6.0 ± 1.0 nM, respectively) and
demonstrates potent inhibition of WNT-dependent signaling
using our previously described inducible luciferase reporter
assay in human embryonic kidney cells (HEK293) that contains
both estrogen receptor-dishevelled (DVL2) and TCF-lucifer-
ase-IRES-GFP constructs (7dF3 IC50 = 5.0 ± 2.0 nM, Table
2);27 it also demonstrates potent activity in LS174T human
colorectal carcinoma cells that harbor a reporter-based readout
measuring constitutive β-catenin mutation-driven WNT path-
way activity (IC50 = 23 ± 11 nM).
27 Compound 6 displays
moderate in vivo clearance in both mouse and rat; however,
high predicted human clearance (∼76% liver blood flow)
prevented further progression (Table 1). Furthermore, the
volumes of distribution (Vd) across all species tested were low
to medium and the aqueous kinetic and thermodynamic
solubilities (94 μM and 0.006 mg/mL, respectively) were
suboptimal. We therefore turned our attention to lowering the
lipophilicity of compound 6 (measured log D = 3.5) with the
aim of decreasing the microsomal and in vivo clearance as well
as improving aqueous solubility. To increase the Vd, we also
attempted the introduction of a weakly basic center.29,30 In the
course of improving physicochemical, pharmaceutical, and
pharmacokinetic properties, we monitored in vitro biochemical
affinity for CDK8 and CDK19 which we found to consistently
predict for cell-based activity in both the reporter-based 7dF3
and LS174T assays;22 we also observed consistent SAR in these
two reporter-based cellular assays for compounds described in
this manuscript (Figure S1 in Supporting Information).
Upon the basis of our work to identify the molecular targets
of 6,22 we knew that extended linear substituents were tolerated
at C-5 of the pyridine ring; therefore, we introduced a variety of
polar groups on the C-5 phenylpyrazole anticipating that these
would enhance metabolic stability and aqueous solubility
(Table 2, entries 2−5). Pleasingly, replacement of the pyrazole
N1-methyl substituent by hydroxyethyl or 2-hydroxy-2-
Scheme 2. General Synthetic Routes to 2-Aminopyridine Derivativesa
aThe asterisk (∗) indicates that KF was added for the synthesis of compounds 76 and 82.
Table 1. Pharmacokinetic Profile of Compound 6a
species Cl (L/h/kg) LBF (%) Vd (L/kg) F (%) t1/2 (h)
mouse 1.87 31 1.08 54 0.55
rat 1.54 35 1.53 88 0.97
dog 0.84 33 0.74 126 0.70
human prediction ∼0.88 ∼76 ∼0.85 ∼70 ∼0.70
aDose: 0.2 mg/kg (iv), 0.5 mg/kg (po).
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methylpropyl led to a significant improvement in microsomal
stability in all species; furthermore, aqueous solubility also
increased (Table 2, entries 2 and 3) while CDK8/19
biochemical affinity and cell-based 7dF3 potency were
maintained. Introduction of a basic center resulted in a 4-fold
drop in potency in both biochemical and cell-based assays,
suggesting that permeability is not responsible for the observed
decrease (Table 2, entries 4−6). However, we noticed that
compounds such as 17, 18, and 21 (Table 2, entries 2, 3, 6) had
reduced microsomal clearance (Clint), which confirmed that the
introduction of polarity could be fruitful. Replacement of
methylpyrazole by fused 6,5-heterocycles was also investigated.
Introduction of 5-substituted-1,3-dihydrobenzo[c]isothiazole
2,2-dioxide (henceforth abbreviated to sultam) improved the
microsomal stability of the molecule across all species tested
(Table 2, entry 7). Furthermore, the thermodynamic aqueous
solubility of 22 was improved by 120-fold; however a 23-fold
drop in cell-based potency was also observed. In order to
improve cell permeability by lowering H-bond donor count, the
N-methyl sultam derivative 23 was prepared (Table 2, entry 8);
while this compound was potent in the 7dF3 cell-based assay,
both 23 and its regioisomer 24 exhibited significant metabolic
instability (Table 2, entries 8 and 9). The aminoindazole 25
gave an acceptable in vitro clearance profile across all species
and high aqueous solubility (Table 2, entry 10); however, as for
most of the derivatives in Table 2, we observed low oral
bioavailability and no improvement of the in vivo mouse
clearance compared to 6.
To understand whether the introduction of polarity
influenced binding mode, we determined the crystal structure
of aminoindazole derivative 25 in complex with the kinase
domain of CDK8 and cyclin C (Figure 1, panel A). As
previously observed with 6, analog 25 occupies the ATP
binding site (Figure 1, panel B).22 All interactions were
conserved including a cation−π interaction of the indazole
phenyl ring with Arg365 due to insertion of the C-terminal
domain of CDK8 into the ATP binding site.22 Notably, binding
to the hinge via the pyridine is conserved despite the
Table 2. Introduction of Polarity at the Pyridine C-5 Substituent
aFree base. bTFA salt. cRun in different conditions (see reporter displacement assay in Experimental Section). dIn this case the chloro substituent is
at C-5 according to nomenclature 8-(3-(3-amino-1H-indazol-6-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one.
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introduction of a potential alternative 3-aminoindazole hinge-
binding motif; pleasingly, the only difference we observe
between the binding modes of compounds 6 and 25 is the
presence of a DMSO molecule in a small pocket adjacent to 25
(see Figure 1, panel A).
Although the N-methyl sultam group conferred metabolic
instability (Table 2, entry 8), its beneficial effect on the potency
was very attractive and we were keen to explore replacement of
the spirolactam in combination either with the N-methyl sultam
or with our hitherto preferred 4-(1-methyl-1H-pyrazol-4-
yl)phenyl substituent at C-5. Consistent with our desire to
replace the spirolactam with more polar heterocycles, mass
spectrometry-mediated metabolite identification for 6 indicated
that the spirolactam was the main site of oxidative metabolism
(data not shown). Introduction of a carbamate (Table 3, entry
3) resulted in >100-fold decrease in CDK8 affinity, whereas
isomer 41 had a potency profile similar to 6 suggesting that a
hydrogen-bond-mediated interaction from the carbamate NH
of compound 41 with Asp173 is required for potency (Table 3,
entry 4). Compound 42 (Table 3, entry 5), which combines the
optimal carbamate isomer and an N-methyl sultam, gave very
potent CDK8/19 affinity with improved metabolic stability
compared to 6. However, in vivo clearance in mice was higher
than that of compound 6. Addition of two methyl groups to
block metabolically vulnerable sites in the spirocycle did not
lead to improved metabolic stability, and a drop in potency was
also observed (Table 3, entry 6). Crystallization of compound
42 (Table 3, entry 5) in CDK8/cyclin C confirmed the
carbamate NH hydrogen bond interaction with Asp173 and
showed interaction of the carbamate carbonyl group with Lys52
(Figure 2).
Cognizant of blocking oxidative metabolism on the
spirolactam, we prepared additional polar derivatives where
the lactam was replaced by imidazolidin-4-one, imidazolidine-
2,4-dione, 2-methylimidazol-5-one, and piperazine-2,5-dione
(Table 3, entries 7−11). Pleasingly, all derivatives were
significantly more stable in microsomal clearance assays;
however, translation to cell-based potency was eroded for the
imidazolidine-2,4-dione, 2-methylimidazole-5-one, and piper-
azine-2,5-dione derivatives (Table 3, entries 8−11) and no
examples demonstrated significant improvement in in vivo
mouse clearance (Table 3, entries 7−11). Surprisingly, the 3-
methylpyrazolone derivative 49 (Table 3, entry 12) led to a 13-
fold improvement in potency in the 7dF3 assay compared to 23
(Table 3, entry 2) but suffered from poor metabolic stability
which was not overcome by exchanging the methyl for a
trifluoromethyl group (Table 3, entry 13). Given that the lower
dynamic range of our in vitro biochemical assays for CDK8 and
CDK19 is approximately 3 nM due to the concentration of
enzyme (5 and 6.7 nM, respectively), it is possible that the
exquisite cell-based potency for compound 49 is on-target.
Introduction of a basic center (compound 51, entry 14)
demonstrated that polarity was tolerated at the piperidine C-4
position, but all analogs were metabolically unstable. Un-
surprisingly, spiropyrrolidine 52 (Table 3, entry 15) led to a
less active compound due to removal of the carbonyl group and
loss of interaction with Lys52.
As noted above, a DMSO-filled pocket was observed in the
X-ray crystal structure of 25 (Figure 1, panel A), and we
postulated that potency could be regained by targeting this
region. Addition of a linker on the pyrrolidine nitrogen (Table
3, entries 16−19) led to a 4-fold improvement in potency;
however, the metabolic stability of such compounds was poor
and, disappointingly, cocrystallization of 54 in CDK8/cyclin C
did not demonstrate electron density consistent with binding of
the pendant methoxyethyl moiety in the DMSO pocket (Figure
3). Despite its high in vivo clearance, the spirocarbamate 42
(Table 3, entry 5) was attractive from its in vitro profile and we
considered spirocarbamate as a potential replacement for the
spirolactam in our further optimization.
Next, we investigated variation of the pyridine C-3 position
(Table 4). We had previously demonstrated that small
lipophilic residues were tolerated at this position consistent
with the protein−ligand crystal structure of 6, 25, and 42 in
CDK8/cyclin C where the pyridine C3 substituent is proximal
to the lipophilic gatekeeper residue Phe97.27 3-Fluoro
derivatives (Table 4, entries 1−4) led to a decrease in both
biochemical and cell-based potency consistent with a weaker
lipophilic interaction of fluorine compared to chlorine with
Phe97.31 Pleasingly, the combination of either spirolactam or
spirocarbamate with the N-methyl sultam and C-3 fluoro group
resulted in acceptable potency and good solubility; however,
both 61 and 63 showed high in vivo clearance in mouse
pharmacokinetics (Table 4, entries 2 and 4). Introduction of a
C-3 trifluoromethyl group restored potency for spirolactams 70
and 71 (Table 4, entries 5−6); however, they proved
Figure 1. Crystal structure of 25 in CDK8/cyclin C (panel A, PDB code 5FGK). Overlay of 6 (pink) and 25 (gray) in CDK8/cyclin C (panel B).
DMSO is colored cyan.
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metabolically unstable. Carbamate 72, despite being surpris-
ingly less potent than the spirolactam 70, had an acceptable
Clint profile and in vivo mouse clearance similar to 6. However,
due to the consistently poor aqueous solubility of these CF3
derivatives, we did not progress them further.
The protein−ligand crystal structure of 25 in CDK8/cyclin C
demonstrates that the C2-H of the pyridine is proximal to the
backbone carbonyl of Asp98 (distance of 2.3 Å, Figure 1), an
observation consistent with our previously reported crystal
structure of 6 in CDK8/cyclin C.22 We hypothesized that
introduction of a hydrogen bond donor at the 2 position of the
pyridine could form a favorable interaction with the backbone
carbonyl of Asp98. Pleasingly, introduction of a 2-amino group
(85, Table 5, entry 1) maintained potency with acceptable
metabolic stability and pharmacokinetics, albeit with poor
aqueous solubility. At this stage, we decided to introduce the 2-
amino functionality into selected optimal compounds from
Tables 2, 3, and 4. Similar to 85, all additional 2-aminopyridines
(Table 5, entries 2−11) were significantly more metabolically
stable than their corresponding pyridine matched pair. For
example, the 2-aminopyridine 87 was at least 5-fold more stable
in mouse Clint experiments than 25. The presence of the 2-
amino functionality also led to lower mouse in vivo clearance;
for example, 92 (Table 5, entry 8, Cl = 1.28 L/h/kg) compared
to its pyridine matched pair 61 (Table 4, entry 2, Cl = 7.9 L/h/
kg). However, we became concerned that reducing in vitro
mouse metabolic Clint to <10 μL/min/mg (Table 5, entry 6)
did not translate to improved mouse in vivo clearance. Thus, in
vitro Clint did not appear to be a sufficient predictor of in vivo
clearance for this series. Predicted mouse blood clearance
(parallel tube model) was estimated from the Clint data to take
into account the polarity of the compounds and their
nonspecific protein binding in in vitro clearance assays;
however, this method also failed to explain the discrepancy
between in vitro and in vivo data (Figure 4).
We hypothesized that the increased in vivo clearance in
comparison with the in vitro predicted clearance may be driven
by active transport. Caco-2 assay data confirmed that most
compounds had a high efflux ratio (ER) (Table S1). However,
it was unclear if the lack of correlation between predicted and
observed blood clearance (calculated from measured plasma
clearance data) was due to a P-glycoprotein (P-gp) transporter
liability (Figure 4). To clarify this matter, we conducted
pharmacokinetic evaluation in P-gp knockout (KO) mice for a
set of compounds (Table 6). We observed lower in vivo
clearance in P-gp KO mice for compounds 42, 48, and 90,
while clearance remained unchanged for both 6 and 89 that did
Table 3. continued
aFree base. bTFA salt. cThe chloro substituent is at C-5 according to 5-(5-chloro-4-(1-methyl-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-
1,3-dihydrobenzo[c]isothiazole 2,2-dioxide. dThe chloro substituent is at C-5 according to 5-(5-chloro-4-(1-(2-methoxyethyl)-1,8-diazaspiro[4.5]-
decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide. eThe chloro substituent is at C-5 according to 5-(5-chloro-4-(1-(3-
methoxypropyl)-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide. fThe chloro substituent is at C-5
according to 5-(5-chloro-4-(1-(3-(methylsulfonyl)propyl)-1,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-
dioxide.
Figure 2. Overlay of lactam 6 (brown) and carbamate 42 (cyan) in
CDK8/cyclin C, PDB code 5HBE.
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not exhibit efflux in the Caco-2 assay. Furthermore, in P-gp KO
mice we noted a lower percentage of parent compound cleared
unchanged in the feces compared to wild-type mice for all
compounds (Table 6). Taken together, these data are
consistent with the notion that transporter-mediated hepatic
uptake and elimination contribute to the overall clearance of
some compounds in this series. However, we noted that even in
the P-gp KO mice, compounds 48 and 90, both of which have
low Clint, demonstrate moderate in vivo clearance and that
compound 48 is still observed in the feces of P-gp KO mice,
Figure 3. Crystal structure of 54 in CDK8/cyclin C (panel A, PDB code 5HBH). Overlay of 25 (gray) with 54 (green) in CDK8/cyclin C (panel B).
Table 4. Introduction of Chlorine Replacements at the Pyridine C-3 Position
aFree base. bTFA salt. cThe CF3 substituent is at C-5 according to 8-(3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-(trifluoromethyl)pyridin-4-yl)-2,8-
diazaspiro[4.5]decan-1-one. dThe CF3 substituent is at C-5 according to 8-(3-(1-methyl-2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-5-
(trifluoromethyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one. eThe CF3 substituent is at C-5 according to 8-(3-(4-(1-methyl-1H-pyrazol-4-
yl)phenyl)-5-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one.
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suggesting that additional nonhepatic elimination mechanisms
are also involved.
To understand the contribution of physicochemical param-
eters to efflux, we conducted a more detailed analysis of the
Caco-2 data. Cognizant of the potential for variability in Caco-2
assay data,32 we classified compounds into two large data sets,
pyridines (n = 165) and aminopyridines (n = 39), seeking
trends to direct our medicinal chemistry design (Figure 5).
Analysis of physicochemical property trends in the pyridine
series showed that HBD ≤ 2 is necessary but not sufficient to
give ER < 3. The probability of compounds in this series
exhibiting a low efflux ratio could be further improved by
limiting physicochemical properties within the range log P >
2.5, TPSA < 80−100, HBA ≤ 7 with no basic center. Analysis
of physicochemical properties versus efflux ratio in a Madin−
Darby canine kidney epithelial cell line (MDCK), transfected to
express human P-gp (MDR-MDCK), led to broadly similar
trends. Analysis of Caco-2 data in the 2-aminopyridine series
indicated that physicochemical properties in the range HBD ≤
3 and TPSA < 100 or HBD ≤ 3 and log P > 3 are necessary for
low efflux in this chemical series, and a combination of HBD ≤
3, TPSA < 100, and log P > 3 is more likely to lead to a low
efflux ratio. These observations are consistent with previously
published studies demonstrating that a fine balance of
physicochemical properties is often required to achieve
Table 5. 2-Aminopyridine Derivatives
aFree base. bTFA salt.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01685
J. Med. Chem. 2016, 59, 1078−1101
1086
potency, metabolic stability, and low efflux in a single
molecule.33,34
Cognizant of these analyses, we set out to reduce efflux in
both the pyridine and 2-aminopyridine series. In the pyridine
series, compound 25 (Table 7, entry 1) has an attractive
solubility coupled with low Clint and acceptable potency;
however, this compound harbors four hydrogen bond donors
with an efflux ratio of >1200. Alkylation of the 3-aminoindazole
nitrogen in 25 significantly reduced Caco-2 efflux but to the
detriment of metabolic stability and potency (Table 7, entries
2−4). Methylation of the hydantoin (Table 7, entry 6) also led
to a lower efflux ratio compared to the parent compound 45,
again to the detriment of microsomal stability. The potent,
metabolically stable, and soluble compound 44 (Table 7, entry
7) bears two hydrogen bond donors and exhibits an efflux ratio
of 3.7. Methylation of the N-1 nitrogen of the imidazolidinone
ring reduced the efflux ratio (Table 7, entry 8); however, poor
microsomal stability was again observed. Replacement of the
methyl group by a variety of substituents including trifluoro-
ethyl did not improve the microsomal stability (Table 7, entry
9). As these attempts proved unsuccessful, we turned our
attention to the aminopyridine series.
In the 2-aminopyridine series, the presence of additional
hydrogen bond donor functionality by virtue of the 2-amino
substituent restricted our freedom to modulate physicochemical
properties in the remainder of the molecule. Thus, the choice of
spirolactam isostere was diminished and we hypothesized that
introduction of more lipophilic C5-pyridine substituents may
be necessary to stay within our desired physicochemical
property range and maximize the chances of low efflux ratios.
Thus, we introduced an isopropylpyrazole at C-5 in
combination with the spirolactam at C-4 of the 2-amino-
pyridine scaffold. This tactic led to suboptimal human Clint and
an efflux ratio of 7 (Table 8, entry 1). We then combined the
spirolactam and spirocarbamate with a methylindazole (Table
8, entries 2 and 3). The spirolactam derivative 109 (measured
log D = 2.5) was potent (CDK8 IC50 = 4.9 ± 0.6 nM, CDK19
IC50 = 2.6 ± 0.4 nM with residence times of 53 and 86 min,
respectively, in the reporter displacement assay), soluble, and
stable with a low efflux ratio and acceptable in vivo mouse
pharmacokinetics (Cl = 0.61 L/h/kg, F = 30%, Table 9);
however, the carbamate matched pair 110 was less potent and
subject to increased efflux. To further improve the metabolic
stability, we prepared compound 111 bearing an N-
isopropylindazole; however, this compound was less stable in
all species. Crystallization of 109 in CDK8/cyclin C (Figure 6)
demonstrated a binding mode consistent with those previously
observed, and pleasingly, a new hydrogen bond interaction
between the exocyclic nitrogen of the 2-aminopyridine scaffold
and the backbone carbonyl of Asp98 was observed (3.0 Å).
In light of its promising profile, compound 109 was further
profiled in rat and dog pharmacokinetics (Table 9). Moderate
clearance was observed in both species; furthermore, the
human pharmacokinetic prediction for 109 was significantly
better than for compound 6 (Tables 9 and 1, respectively,
∼31% of liver blood flow for 109 compared to ∼76% for 6).
Pleasingly, compound 109 had acceptable aqueous solubility
(Table 8, entry 2) and demonstrated minimal activity when
tested in a panel of 55 receptors, ion channels, and enzymes at
1 μM (Tables S2 and S3) and in a panel of 279 kinases (Table
S4); weak inhibition of CYPs was observed (Table S5).
Consistent with the profile of chemical probe 6, compound 109
demonstrated potent inhibition of reporter-based readouts
measuring basal WNT pathway activity in human cancer cell
lines that have constitutively activated WNT pathway signaling:
LS174T (β-catenin mutant), SW480 and Colo205 (APC
mutant) or PA-1 human teratocarcinoma cells that are WNT
ligand dependent (Table 10).
Compound 109 was then assessed in the in vivo APC-mutant
SW620 human colorectal carcinoma xenograft model, treating
established tumors in female NCr athymic mice. Mice were
treated orally (30 mg/kg q.d.) for 15 days; a 54.2% reduction in
tumor weight was observed at day 15 (Figure 7, panels A and
B). We monitored inhibition of STAT1SER727 phosphorylation,
which we have previously demonstrated to be an in vitro cell-
based and in vivo pharmacodynamic biomarker of CDK8
inhibition.22 Reduced STAT1SER727 phosphorylation was
maintained for more than 6 h after the last dose (Figure S2)
consistent with measured free plasma and tumor exposures that
remained above CDK8 IC50 (Figure 7, panel C, Figure S3, and
Table S6). In light of its potent and selective profile coupled
with good oral pharmacokinetics and duration of in vivo target
engagement on oral dosing, compound 109 (CCT251921) has
been selected for progression into further preclinical in vivo
efficacy and safety studies.
■ CONCLUSIONS
Literature evidence9−16 and our own studies22 point to a role
for the Mediator complex-associated kinases CDK8 and
CDK19 in human disease, particularly in colorectal cancer
where CDK8 has been reported as a putative oncogene.
CDK19, a paralogue of CDK8, is relatively unexplored, and our
previous studies demonstrate that selectivity for CDK8 over
CDK19 with a small molecule ligand is likely to be
Figure 4. In vitro−in vivo correlation of clearance for compounds
from the pyridine and 2-aminopyridine series. X axis is calculated
blood clearance from measured plasma clearance in mouse PK. Y axis
is predicted blood clearance using the parallel tube model.
Table 6. Pharmacokinetic Profile of a Set of Compounds in
Wild-Type and P-gp KO Mice



















6 2.5 141 2.34 9.1 2.30 <1
89 2.0 18.5 2.59 17 2.84 <1
42 4.7 57 4.89 18 4.00 <1
90 14.8 <10 4.08 20 2.85 <1
48 17.6 30 4.43 67 2.22 24
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challenging.22 Indeed, in our recently reported discovery of
CCT251545 (6), a potent and selective chemical probe for the
further exploration of CDK8 and CDK19 pharmacology, we
show strong correlation of CDK8 and CDK19 binding
affinity.22
Here, we have further optimized the small molecule CDK8/
19-selective chemical probe 6 to give compound 109 by
improving oral pharmacokinetics and pharmaceutical properties
in order to facilitate further in vivo evaluation of CDK8/19
pharmacology and progression into preclinical in vivo efficacy
and safety studies. Chemical probe 6, although a high affinity
ligand for CDK8 and CDK19, displays moderate in vivo
clearance in preclinical species resulting in a clearance
prediction to man that may preclude consistent target
engagement for extended periods of time; in addition, aqueous
solubility was suboptimal and we anticipated that this may limit
the maximum absorbable dose. In attempting to reduce
oxidative metabolism by reducing lipophilicity while maintain-
ing key interactions within the CDK8 kinase domain, we
benefited from detailed knowledge of the binding mode of 6
Figure 5. Physicochemical property analysis results for pyridine and aminopyridine series.
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and analogs through protein−ligand crystal structures in the
CDK8 kinase domain. We were able to improve in vitro
metabolic stability by introducing a C-2 amino substituent to
the pyridine scaffold which reinforced interactions with the
kinase hinge region and reduced compound lipophilicity.
However, we identified transporter-mediated hepatic uptake
as a component of in vivo clearance. In particular, we noted that
a significant number of compounds in both the pyridine and 2-
aminopyridine series exhibited higher measured in vivo
clearance than predicted by experimental in vitro clearance
assessment. Through careful correlation of in vitro Caco-2
efflux ratios with physicochemical properties and subsequent
medicinal chemistry design within desirable physicochemical
property ranges, we were able to identify compounds that
demonstrated reduced clearance without increased suscepti-
bility to active hepatic uptake. Compound 109 was identified as
the best compromise of in vitro biochemical and pharmacoki-
netic properties that demonstrated acceptable in vivo
pharmacokinetics suitable for progression to in vivo animal
models of cancer. Further in vivo evaluation of 109 will be
reported in due course.
■ EXPERIMENTAL SECTION
Chemistry. Commercially available starting materials, reagents, and
dry solvents were used as supplied. Column chromatography was
performed on a Biotage SP1 purification system using Thomson or
Biotage Flash silica cartridges or on a Companion purification system
using Interchim silica cartridges. Preparative TLC was performed on
Merck plates. Ion exchange chromatography was performed using
acidic Isolute Flash SCX-II columns or basic Isolute Flash NH2
columns. Preparative HPLC was conducted according the following
methods. For method A, injections of the sample were made onto a
SunFire C18 OBD column (100 Å, 5 μm, 30 mm × 100 mm).
Chromatographic separation at room temperature was carried out
using Agilent Tehnologies, 1260 Infinity, acetonitrile/water gradient
(both modified with 0.1% formic acid) at a flow rate of 50 mL/min.
For method B, injections of the sample were made onto a
Phenomenex Gemini column (10 μm, 250 mm × 21.2 mm, C18,
Phenomenex, Torrance, CA, USA). Chromatographic separation at
room temperature was carried out using Gilson GX-281 liquid handler
Table 7. Attempts To Reduce Efflux in the Pyridine Seriesd
aFree base. bTFA salt. cIn this case the chloro substituent is at C-5 according to nomenclature 8-(3-(3-amino-1-methyl-1H-indazol-6-yl)-5-
chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one. dM: mouse. R: rat. H: human. log P was calculated using Percepta Batch, version 2015 (www.
acdlabs.com). TPSA was calculated in the program MOE (www.chemcomp.com).
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system combined with a Gilson 322 HPLC pump (Gilson, Middleton,
WI, USA) over a 15 min gradient elution from 40:60 to 100:0 MeOH/
water (both modified with 0.1% formic acid) at a flow rate of 20 mL/
min. 1H NMR spectra were recorded on a Bruker Avance 500, Bruker
Avance 400, or Avance II 400. Samples were prepared as solutions in a
deuterated solvent and referenced to the appropriate internal
nondeuterated solvent peak. 13C NMR spectra were recorded at 126
MHz using an internal deuterium lock. The following internal
references were used: CDCl3 (δC 77.2), CD3OD (δC 49.0), and
DMSO-d6 (δC 39.5); unobserved resonances for quaternary carbon
atoms are denoted by “Cq not observed”. LC/MS and HRMS analyses
were performed on an Agilent 1200 series HPLC and diode array
detector coupled to a 6210 time-of-flight mass spectrometer with dual
multimode APCI/ESI source. Analytical separation was carried out
according to the following methods. For method A, analytical
separation was carried out on a Chromolith Speed ROD column
(RP-18e, 50 mm × 4.6 mm) using a flow rate of 2.4 mL/min in a 3.9
min gradient elution with detection at 220 nm. The mobile phase was
a mixture of water containing 0.05% formic acid (solvent A) and
acetonitrile containing 0.04% formic acid (solvent B). Gradient elution
was as follows: 95:5 (A/B) to 0:100 (A/B) over 2.8 min, 0:100 (A/B)
for 0.5 min, and then reversion back to 95:5 (A/B) over 0.1 min,
finally 95:5 (A/B) for 0.5 min. For method B, analytical separation was
carried out on a Chromolith Performance column (RP-18e, 100 mm ×
3 mm) using a flow rate of 2.0 mL/min in a 4.8 min gradient elution
with detection at 220 nm. The mobile phase was a mixture of water
(solvent A) and acetonitrile (solvent B) both containing 0.1% TFA.
Gradient elution was as follows: 99:1 (A/B) over 0.2 min, then 99:1 to
0:100 (A/B) over 3.6 min, 0:100 (A/B) for 0.4 min, and then
reversion back to 99:1 (A/B) over 0.1 min and finally 99:1 (A/B) for
0.5 min. For method C, analytical separation was carried out at 30 °C
on a Merck Purospher STAR column (RP-18e, 30 mm × 4 mm) using
a flow rate of 1.5 mL/min in a 4 min gradient elution with detection at
254 nm. The mobile phase was a mixture of MeOH (solvent A) and
water (solvent B), both containing 0.1% formic acid. Gradient elution
was as follows: 1:9 (A/B) to 9:1 (A/B) over 2.5 min, 9:1 (A/B) for 1
min, and then reversion back to 1:9 (A/B) over 0.3 min, finally 1:9
(A/B) for 0.2 min. For method D, analytical separation was carried out
at 30 °C on a Merck Purospher STAR column (RP-18e, 30 mm × 4
mm) using a flow rate of 1.5 mL/min in a 4 min gradient elution with
Table 8. Reducing Efflux in the 2-Aminopyridine Seriesd
afree base. bTFA salt. cbesylate salt. dM: mouse. R: rat. H: human.
Table 9. Pharmacokinetic Profile of 109a
species Cl (L/h/kg) LBF (%) Vd (L/kg) F (%) t1/2 (h)
mouse 0.61 10 0.63 30 0.78
rat 1.49 34 2.0 57 1.10
dog 1.07 43 1.4 68 0.99
human prediction ∼0.36 ∼31 ∼1.4 ∼70 ∼2.7
aDose: 0.2 mg/kg (iv), 0.5 mg/kg (po).
Figure 6. X-ray crystal structure of 109 in CDK8/cyclin C, PDB code
5HBJ.
Table 10. Potency of 6 and 109 versus Reporter-Based
Readouts of WNT Pathway Activity in Human Cancer Cell
Lines
cell line WNT pathway activation 6 IC50 (nM) 109 IC50 (nM)
LS174T β-catenin mutant 23 ± 11 33 ± 13
SW480 APC-mutant 190 ± 30 22 ± 2
Colo205 APC-mutant 35 ± 3 15 ± 1
PA-1 WNT ligand-dependent 20 ± 10 64 ± 34
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detection at 220 nm. The mobile phase was a mixture of MeOH
(solvent A) and water (solvent B), both containing 0.1% formic acid.
Gradient elution was as follows: 1:9 (A/B) to 9:1 (A/B) over 2.5 min,
9:1 (A/B) for 1 min, and then reversion back to 1:9 (A/B) over 0.3
min, finally 1:9 (A/B) for 0.2 min. For method E, analytical separation
was carried out on XBridge C8 column (50 mm × 4.6 mm, 3.5 μm)
using a flow rate of 2.0 mL/min in a 10 min gradient elution with
detection at 254 nm. The mobile phase was a mixture of acetonitrile
(solvent A) and water (solvent B), both containing 0.1% TFA.
Gradient elution was as follows: 5:95 (A/B) to 100:0 (A/B) over 8
min, 100:0 (A/B) for 0.1 min, and then reversion back to 5:95 (A/B)
over 0.4 min, finally 5:95 (A/B) for 1.5 min. The following reference
masses were used for HRMS analysis: caffeine [M + H]+ 195.087 652;
(hexakis(1H,1H,3H-tetrafluoropentoxy)phosphazene [M + H]+
922.009 798) and hexakis(2,2-difluoroethoxy)phosphazene [M + H]+
622.028 96 or reserpine [M + H]+ 609.280 657. All compounds
submitted for biological testing were determined to be >95% pure by
method A, B, C, D, or E unless stated otherwise.
Preparation of Compounds in Table 2, Exemplified by
Compounds 23 and 25. 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-dihydrobenzo[c]isothiazole 2,2-Diox-
ide (14). 2-Chlorobenzylsulfonyl chloride (1.86 g, 8.26 mmol) was
dissolved in acetone (27 mL), and then ammonium hydroxide (18
mL) was added. The reaction mixture was stirred for 2.5 h at rt, and
the solvent was evaporated. The reaction mixture was diluted with
EtOAc, and water was added. The two layers were separated, and the
aqueous layer was extracted with EtOAc. The combined organic layers
were dried over MgSO4 and concentrated under vacuum. The crude
product was purified by Biotage column chromatography (cyclo-
hexane/acetone 90:10 to 60:40) to afford (2-chlorophenyl)-
methanesulfonamide as a white solid (1.6 g, 94% yield). 1H NMR
(500 MHz, CDCl3) δ 7.56−7.53 (m, 1H), 7.47−7.44 (m, 1H), 7.36−
7.30 (m, 2H), 4.66 (bs, 2H), 4.57 (s, 2H); LC−MS (method D, ESI,
m/z) tR = 1.77 min, parent does not ionize.
(2-Chlorophenyl)methanesulfonamide (450 mg, 2.19 mmol),
tris(dibenzylideneacetone)dipalladium (100 mg, 0.109 mmol), 2-di-
tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (186 mg, 0.438
mmol), and potassium carbonate (605 mg, 4.38 mmol) were loaded
in a microwave vial, and THF (8.8 mL) was added. The reaction
mixture was stirred at 80 °C in an oil bath for 13 h before being
quenched with a sat. aq NH4Cl solution. The solvent was then
evaporated and the residue was purified by Biotage column
chromatography (cyclohexane/acetone 95:5 to 60:40) to afford 1,3-
dihydrobenzo[c]isothiazole 2,2-dioxide as a white solid (296 mg, 80%
yield). 1H NMR (500 MHz, CDCl3) δ 7.31−7.26 (m, 1H), 7.26−7.23
(m, 1H), 7.07 (td, J = 7.6, 0.9 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.48
(bs, 1H), 4.39 (s, 2H); LC−MS (method D, ESI, m/z) tR = 1.69 min,
parent does not ionize.
To a suspension of 1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (280
mg, 1.66 mmol) and potassium carbonate (229 mg, 1.66 mmol) in
DMF (5 mL) was added iodomethane (414 μL, 6.62 mmol). The
reaction mixture was stirred for 6 h at rt and was then quenched with a
sat. NH4Cl solution. The reaction mixture was concentrated and
purified by Biotage column chromatography (cyclohexane/acetone
90:10 to 70:30) to afford 1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-
dioxide as a white solid (270 mg, 89% yield). 1H NMR (500 MHz,
CDCl3) δ 7.37−7.32 (m, 1H), 7.27−7.24 (m, 1H), 7.02 (td, J = 7.6,
1.0 Hz, 1H), 6.73 (d, J = 8.0 Hz, 1H), 4.34 (s, 2H), 3.14 (s, 3H); LC−
MS (method D, ESI, m/z) tR = 2.07 min, parent does not ionize.
1-Methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (272 mg, 1.49
mmol) was dissolved in DMF (1.5 mL), and N-bromosuccinimide
(264 mg, 1.49 mmol) was added. The reaction mixture was stirred at rt
for 4 h. After addition of water, the reaction mixture was concentrated.
The residue was purified by Biotage column chromatography
(cyclohexane/acetone 90:10 to 70:30) to afford 5-bromo-1-methyl-
1,3-dihydrobenzo[c]isothiazole 2,2-dioxide as a white solid (330 mg,
85% yield). 1H NMR (500 MHz, CDCl3) δ 7.45−7.41 (m, 1H), 7.37−
7.35 (m, 1H), 6.59 (d, J = 8.5 Hz, 1H), 4.30 (s, 2H), 3.09 (s, 3H);
LC−MS (method C, ESI, m/z) tR = 2.46 min, parent does not ionize.
5-Bromo-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (267
mg, 1.02 mmol), bis(pinacolato)diboron (388 mg, 1.53 mmol),
potassium acetate (300 mg, 3.06 mmol), and Pd(dppf)Cl2·CH2Cl2 (42
mg, 0.051 mmol) were loaded in a microwave vial, and DME (7.4 mL)
was added. The reaction mixture was stirred in an oil bath at 80 °C
overnight. The reaction was concentrated and purified by Biotage
column chromatography (cyclohexane/acetone 97:3 to 85:15) to
afford 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-
dihydrobenzo[c]isothiazole 2,2-dioxide 14 as a white solid (290 mg,
92% yield). 1H NMR (500 MHz, CDCl3) δ 7.80−7.77 (m, 1H), 7.69−
7.67 (m, 1H), 6.71 (d, J = 8.0 Hz, 1H), 4.32 (s, 2H), 3.15 (s, 3H), 1.33





dihydrobenzo[c]isothiazole 2,2-dioxide 14 (58 mg, 0.19 mmol), 8-
(3-bromo-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one27 8
(54 mg, 0.16 mmol), and Pd(dppf)Cl2·CH2Cl2 (6.4 mg, 7.9 μmol)
were loaded in a microwave vial, and then 0.5 M sodium carbonate in
water (440 μL, 0.220 mmol) and acetonitrile (2.8 mL) were added.
The reaction was heated at 120 °C for 60 min under microwave
Figure 7. Reduction of (A) tumor volume and (B) tumor weight
versus vehicle-treated controls after chronic oral dosing (30 mg/kg
q.d.) of 109 to an APC-mutant SW620 human colorectal carcinoma
xenograft animal model. (C) Free plasma and free tumor exposure
(nM) at 1, 2, 6, and 24 h after the last dose in the same experiment.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01685
J. Med. Chem. 2016, 59, 1078−1101
1091
irradiation. The solvent was evaporated and the crude material was
purified by Biotage column chromatography (DCM/EtOH 99:1 to
85:15) to give 8-(3-chloro-5-(1-methyl-2,2-dioxido-1,3-dihydrobenzo-
[c]isothiazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 23 as a
white solid (57 mg, 81% yield). 1H NMR (500 MHz, CDCl3) δ 8.42
(s, 1H), 8.17 (s, 1H), 7.29−7.24 (m, 2H), 6.81 (d, J = 8.1 Hz, 1H),
6.36 (s, 1H), 4.48 (s, 2H), 3.31 (t, J = 6.8 Hz, 2H), 3.18 (s, 3H), 3.16−
3.10 (m, 2H), 2.81 (t, J = 11.2 Hz, 2H), 1.98 (t, J = 6.8 Hz, 2H), 1.91−
1.80 (m, 2H), 1.39−1.33 (m, 2H); 13C NMR (126 MHz, CDCl3) δ
181.6, 153.0, 150.4, 149.9, 141.5, 133.2, 131.0, 130.3, 128.3, 126.6,
118.0, 109.1, 50.8, 47.7, 41.6, 38.8, 32.4, 32.2, 26.6; LC−MS (method
C, ESI, m/z) tR = 2.00 min, 447/449 (M + H)
+; ESI-HRMS calcd for
C21H24
35ClN4O3S (M + H)
+ 447.1252, found 447.1247.
(3-Amino-1H-indazol-6-yl)boronic Acid Hydrochloride (16).
In a screw-capped vessel, 6-bromo-1H-indazol-3-amine (95% purity,
500 mg, 2.36 mmol) and 4-(dimethylamino)pyridine (58 mg, 0.47
mmol) were dissolved in THF (10 mL). Di-tert-butyl dicarbonate
(2.52 mL, 11.8 mmol) and triethylamine (3.27 mL, 23.6 mmol) were
added, and the reaction solution was stirred for 3 days at rt. The
reaction mixture was diluted with water (100 mL) and the aqueous
layer extracted with EtOAc. The organic layer was washed with water,
dried, filtered, and evaporated to dryness to give tert-butyl 3-[bis(tert-
butoxycarbonyl)amino]-6-bromoindazole-1-carboxylate (1.42 g, 73%
pure, 86% corrected yield) as a colorless oil, which was used without
further purification. LC−MS (method B, ESI, m/z) tR = 3.91 min,
534/536 (M + Na)+.
In a screw-capped vessel, tert-butyl 3-[bis(tert-butoxycarbonyl)-
amino]-6-bromoindazole-1-carboxylate (73% pure, 1.34 g, 1.91 mmol)
was dissolved in THF (16 mL). Bis(pinacolato)diboron (486 mg, 1.91
mmol), potassium acetate (375 mg, 3.83 mmol), and Pd(dppf)Cl2·
CH2Cl2 (78 mg, 0.096 mmol) were added, and the red reaction
mixture was stirred for 15 h at 70 °C. Further bis(pinacolato)diboron
(486 mg, 1.91 mmol), potassium acetate (130 mg, 1.33 mmol), and
Pd(dppf)Cl2·CH2Cl2 (78 mg, 0.096 mmol) were added, and stirring
was continued at 70 °C for additional 4 h. The black reaction mixture
was treated with EtOAc, filtered, and evaporated to dryness under
reduced pressure. The dark brown residue was purified by flash
chromatography (heptane/DCM, gradient) to give tert-butyl 3-
[bis(tert-butoxycarbonyl)amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)indazole-1-carboxylate (1.00 g, 90% pure, 84% corrected
yield) as a yellow solid which was used directly in the next step. LC−
MS (method B, ESI, m/z) tR = 3.94 min, 559/560 (M + H)
+.
tert-Butyl 3-[bis(tert-butoxycarbonyl)amino]-6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)indazole-1-carboxylate (90% pure, 1.00 g, 1.61
mmol) was treated with HCl in dioxane (25 mL). The pale yellow
solution was stirred at rt for 15 h. The solution was evaporated to
dryness and the residue was treated with diethyl ether to obtain a beige
solid. The mixture was filtered and the residue was washed with diethyl
ether to afford (3-amino-1H-indazol-6-yl)boronic acid hydrochloride
16 (351 mg, 95% pure, 97% yield) as a beige solid which was used
directly in the next step. LC−MS (method B, ESI, m/z) tR = 1.34 min,
177/178 (M + H)+.
8-(3-(3-Amino-1H-indazol-6-yl)-5-chloropyridin-4-yl)-2,8-
diazaspiro[4.5]decan-1-one (25). 8-(3-Bromo-5-chloropyridin-4-
yl)-2,8-diazaspiro[4.5]decan-1-one27 8 (92% pure, 180 mg, 0.480
mmol) and (3-amino-1H-indazol-6-yl)boronic acid hydrochloride 16
(95% pure, 162 mg, 0.720 mmol) were dissolved in acetonitrile (8
mL), and 0.5 M sodium carbonate in water (2.8 mL, 1.4 mmol) and
Pd(dppf)Cl2·CH2Cl2 (20 mg, 0.020 mmol) were added. The reaction
mixture was stirred for 1 h at 120 °C under microwave irradiation,
diluted with acetonitrile (10 mL), filtered and the filtrate evaporated to
dryness. The residue was purified by preparative HPLC (method A, 20
min gradient elution from 2:98 to 20:80 acetonitrile/water). The pure
fractions were combined and evaporated down to a volume of 20 mL.
The solution was neutralized with solid NaHCO3 and extracted with
EtOAc (3 × 30 mL). The organic layer was dried over Na2SO4 and
evaporated to dryness. The residue was suspended in diethyl ether and
filtered under vacuum to afford 8-(3-(3-amino-1H-indazol-6-yl)-5-
chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 25 (85 mg, 45%
yield) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H),
8.25 (s, 1H), 7.63 (dd, J = 8.2, 0.9 Hz, 1H), 7.29 (s, 1H), 6.97 (dd, J =
8.2, 1.4 Hz, 1H), 5.66 (s, 1H), 3.26 (t, J = 6.8 Hz, 2H), 3.21−3.13 (m,
2H), 2.74 (t, J = 11.7 Hz, 2H), 1.97−1.87 (m, 4H), 1.37−1.29 (m,
2H); 13C NMR (126 MHz, CDCl3) δ 181.4, 153.2, 150.9, 149.9,
148.9, 142.5, 137.1, 134.0, 128.2, 121.6, 119.6, 114.2, 110.3, 47.7, 41.5,
38.7, 32.5, 32.2; LC−MS (method C, ESI, m/z) tR = 1.58 min, 397/
399 (M + H)+; ESI-HRMS calcd for C20H22
35ClN6O (M + H)
+
397.1538, found 397.1522.
Preparation of Compounds in Table 3, Exemplified by
Compounds 42 and 54. 1-Oxa-3,8-diazaspiro[4.5]decan-2-one
(38). 4-Aminomethyl-1-benzylpiperidin-4-ol (25.0 g, 113 mmol) was
suspended in DCM (400 mL), and a solution of triphosgene (32.8 g,
110 mmol) dissolved in DCM (200 mL) was added dropwise while
maintaining the temperature between 30 and 35 °C. The solution
turned yellow and the mixture was stirred at rt overnight. To the
reaction mixture 1 N NaOH solution (200 mL) was added, and the
organic phase was separated, washed with water, dried over sodium
sulfate, filtered, and evaporated to dryness. The residue was triturated
with diethyl ether, the solid obtained was washed with diethyl ether
and dried in vacuo to give 13.2 g (82% pure, 39% corrected yield) of 8-
benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one35 as a yellow solid which
was used in the next step without further purification. LC−MS
(method B, ESI, m/z) tR = 1.49 min, 247 (M + H)
+.
8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (82% pure, 13.2 g,
43.9 mmol) was dissolved in MeOH (60 mL) and THF (60 mL). Pd/
C 5% (54.1% H2O, 3.00 g) was added, and the reaction mixture was
stirred at rt under hydrogen for 18 h. Since the reaction was
incomplete, additional Pd/C 5% (54.1% H2O, 6.00 g) was added and
the reaction mixture was stirred at rt for another 18 h. Another portion
of palladium was added and the reaction was stirred for 18 h. The
catalyst was then filtered off and the filtrate was evaporated to dryness.
The residue was triturated with diethyl ether, filtered, and dried in
vacuum to yield in 5.39 g (78% yield) of 1-oxa-3,8-diazaspiro[4.5]-
decan-2-one 38 as a brown solid which was used directly in the next
step. LC−MS (method B, ESI, m/z) tR = 0.39 min, 157 (M + H)+.
8-(3-Bromo-5-chloropyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]-
decan-2-one (27). In a microwave vial 3-bromo-4,5-dichloropyr-
idine27 7 (2.00 g, 8.80 mmol) was dissolved in NMP (15 mL). 1-Oxa-
3,8-diazaspiro[4.5]decan-2-one 38 (1.65 g, 10.6 mmol) and triethyl-
amine (2.44 mL, 17.6 mmol) were added. The reaction was stirred for
1 h at 220 °C under microwave irradiation. The brown reaction
solution was treated with 300 mL of water. The beige precipitate was
filtered and washed with water and diethyl ether to give 8-(3-bromo-5-
chloropyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 27 (2.34 g,
77% yield) as a beige solid which was used directly in the next step.





[4.5]decan-2-one 27 (2.54 g, 7.33 mmol) was suspended in
acetonitrile (60 mL). 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor-
olan-2-yl)-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide 14 (2.72 g, 8.79
mmol), 0.5 M sodium carbonate in water (29.3 mL, 14.6 mmol), and
(Pd(dppf)Cl2·CH2Cl2 complex (299 mg, 0.366 mmol) were added.
The reaction mixture was stirred at 80 °C for 3 h. After addition of
EtOAc and water, the organic layer was separated and washed with
water, dried over MgSO4, filtered, and evaporated to dryness. The
crude material was purified by flash chromatography (Companion,
DCM/MeOH 100:0 to 90:10) to yield in 1.61 g (49% yield) of 8-(3-
chloro-5-(1-methyl-2,2-dioxido-1,3-dihydrobenzo[c]isothiazol-5-yl)-
pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 42 as a colorless
solid. 1H NMR (500 MHz, DMSO-d6) δ 8.46 (s, 1H), 8.17 (s, 1H),
7.50 (s, 1H), 7.37 (s, 1H), 7.32 (dd, J = 8.2, 1.9 Hz, 1H), 7.08 (d, J =
8.2 Hz, 1H), 4.72 (s, 2H), 3.20 (s, 2H), 3.10 (s, 3H), 2.96−2.82 (m,
4H), 1.77−1.66 (m, 4H); 13C NMR (126 MHz, DMSO-d6) δ 157.7,
152.1, 150.6, 148.8, 141.2, 133.2, 130.2, 130.0, 127.3, 126.0, 118.7,
109.5, 78.7, 50.1, 50.0, 47.1, 35.8, 26.1; LC−MS (method C, ESI, m/z)
tR = 1.87 min, 449/451 (M + H)
+; ESI-HRMS calcd for
C20H22
35ClN4O4S (M + H)
+ 449.1045, found 449.1032.
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8-(3-Bromo-5-chloropyridin-4-yl)-1-(2-methoxyethyl)-1,8-
diazaspiro[4.5]decane (36). To a suspension of 8-boc-1,8-diaza-
spiro[4.5]decane oxalate (202 mg, 0.839 mmol) in acetonitrile (16.8
mL) were added potassium carbonate (348 mg, 2.52 mmol),
potassium iodide (139 mg, 0.839 mmol), and 2-bromoethyl methyl
ether (95 μL, 1.0 mmol). The reaction was heated at 80 °C overnight
and filtered. The filtrate was concentrated and the crude was purified
by Biotage column chromatography (eluting with 1−8% MeOH/aq
NH3 (10:1) in DCM) to give tert-butyl 1-(2-methoxyethyl)-1,8-
diazaspiro[4.5]decane-8-carboxylate (160 mg, 64% yield) as a colorless
oil. 1H NMR (500 MHz, CD3OD) δ 4.11 (br d, J = 14.2 Hz, 2H), 3.53
(t, J = 5.8 Hz, 2H), 3.36 (s, 3H), 3.05−2.67 (m, 6H), 1.89 (s, 4H),
1.67−1.57 (m, 2H), 1.47 (s, 9H), 1.44−1.37 (m, 2H); LC−MS
(method C, ESI, m/z) tR = 1.75 min, 299 (M + H)
+.
3-Bromo-4,5-dichloropyridine27 7 (70 mg, 0.31 mmol) and tert-
butyl 1-(2-methoxyethyl)-1,8-diazaspiro[4.5]decane-8-carboxylate
(120 mg, 0.402 mmol) were introduced in a microwave vial, and
then 1-methoxy-2-propanol (773 μL) and triethylamine (130 μL,
0.928 mmol) were added. The reaction mixture was stirred for 2 h at
220 °C under microwave irradiation. The solvent was evaporated and
the crude material was purified by Biotage column chromatography
(eluting with 2−5% MeOH/aq NH3 (10:1) in DCM) to give 8-(3-
bromo-5-chloropyridin-4-yl)-1-(2-methoxyethyl)-1,8-diazaspiro[4.5]-
decane 36 (86 mg, 72% yield) as a colorless oil. 1H NMR (500 MHz,
CD3OD) δ 8.49 (s, 1H), 8.36 (s, 1H), 3.53 (t, J = 6.0 Hz, 2H), 3.45
(td, J = 12.6, 2.3 Hz, 2H), 3.37 (s, 3H), 3.34−3.28 (m, 2H), 2.91 (t, J
= 6.6 Hz, 2H), 2.76 (t, J = 6.0 Hz, 2H), 2.00−1.85 (m, 6H), 1.46−1.40




isothiazole 2,2-Dioxide (54). 8-(3-Bromo-5-chloropyridin-4-yl)-1-
(2-methoxyethyl)-1,8-diazaspiro[4.5]decane 36 (27 mg, 0.069 mmol),
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-
benzo[c]isothiazole 2,2-dioxide 14 (21 mg, 0.069 mmol), and
Pd(dppf)Cl2·CH2Cl2 (2.8 mg, 3.5 μmol) were loaded in a microwave
vial, and then acetonitrile (1.2 mL) and 0.5 M sodium carbonate in
water (194 μL, 0.0970 mmol) were added. The reaction was stirred at
120 °C for 60 min. The solvents were evaporated and the crude
material was purified by Biotage column chromatography (eluting with
1−5% MeOH/aq NH3 (10:1) in DCM) and further purified by SCX-2
column chromatography (loading with DCM:MeOH, elution with 1 N
NH3 in MeOH) to afford 5-(5-chloro-4-(1-(2-methoxyethyl)-1,8-
diazaspiro[4.5]decan-8-yl)pyridin-3-yl)-1-methyl-1,3-dihydrobenzo[c]-
isothiazole 2,2-dioxide 54 (14 mg, 41% yield) as a colorless oil. 1H
NMR (500 MHz, acetone-d6) δ 8.38 (s, 1H), 8.17 (s, 1H), 7.45 (s,
1H), 7.40−7.37 (m, 1H), 7.05 (d, J = 8.2 Hz, 1H), 4.59 (s, 2H), 3.37
(t, J = 6.5 Hz, 2H), 3.27 (s, 3H), 3.16 (s, 3H), 3.10−3.05 (m, 2H),
2.88−2.73 (m, 4H), 2.60 (t, J = 6.5 Hz, 2H), 1.73−1.59 (m, 6H),
1.16−1.09 (m, 2H); 13C NMR (126 MHz, CD3OD) δ 153.8, 149.6,
148.6, 141.8, 134.2, 130.6, 130.3, 128.0, 126.2, 118.5, 109.0, 71.5, 57.6,
50.8, 49.1, 47.2, 32.3, 31.0, 25.1, 20.0 (Cq and CH2 of the sultam not
observed); LC−MS (method C, ESI, m/z) tR = 1.65 min, 491/493 (M
+ H)+; ESI-HRMS calcd for C24H32
35ClN4O3S (M + H)
+ 491.1878,
found 491.1878.
Preparation of Compounds in Table 4, Exemplified by
Compounds 61, 63, and 72. 8-(3-Bromo-5-fluoropyridin-4-yl)-
2,8-diazaspiro[4.5]decan-1-one (58). 3-Bromo-4-chloro-5-fluoro-
pyridine 57 (300 mg, 1.43 mmol) and tert-butyl 1-oxo-2,8-diaza-
spiro[4.5]decane-8-carboxylate (471 mg, 1.85 mmol) were introduced
in a microwave vial, and 1-methoxy-2-propanol (3.5 mL) and
triethylamine (601 μL, 4.28 mmol) were added. The reaction mixture
was stirred for 1 h at 220 °C under microwave irradiation. The solvent
was evaporated and the crude material was purified by Biotage column
chromatography (DCM/EtOH 98:2 to 92:8) to afford 8-(3-bromo-5-
fluoropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 58 (140 mg, 30%
yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.39 (s, 1H),
8.22 (d, J = 3.6 Hz, 1H), 6.86 (s, 1H), 3.51−3.43 (m, 2H), 3.40−3.35
(m, 2H), 3.24−3.16 (m, 2H), 2.16−2.07 (m, 4H), 1.57−1.50 (m, 2H);
19F NMR (500 MHz, CDCl3) δ −135; LC−MS (method C, ESI, m/z)





one 58 (40 mg, 0.12 mmol), 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide 14 (49
mg, 0.16 mmol), and Pd(dppf)Cl2·CH2Cl2 (4.98 mg, 6.09 μmol) were
loaded in a microwave vial, and acetonitrile (2.1 mL) and 0.5 M
sodium carbonate in water (341 μL, 0.171 mmol) were added. The
reaction was stirred at 120 °C for 60 min under microwave irradiation.
After evaporation of the solvents, the crude material was purified by
Biotage column chromatography (DCM/EtOH 98:2 to 95:5) and by
SCX-2 column chromatography (loading with DCM/MeOH, elution
with 1 N NH3 in MeOH) to give 8-(3-fluoro-5-(1-methyl-2,2-dioxido-
1,3-dihydrobenzo[c]isothiazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]-
decan-1-one 61 (33 mg, 63% yield) as a cream solid. 1H NMR (500
MHz, CDCl3) δ 8.26 (d, J = 4.2 Hz, 1H), 8.09 (s, 1H), 7.47 (dd, J =
8.2, 1.7 Hz, 1H), 7.44 (d, J = 1.7 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H),
5.78 (s, 1H), 4.46 (s, 2H), 3.32 (t, J = 6.9 Hz, 2H), 3.26−3.19 (m,
2H), 3.18 (s, 3H), 3.03−2.94 (m, 2H), 2.05 (t, J = 6.8 Hz, 2H), 1.81
(ddd, J = 13.4, 11.3, 4.2 Hz, 2H), 1.36−1.30 (m, 2H); 19F NMR (500
MHz, CDCl3) δ −139; 13C NMR (126 MHz, CDCl3) δ 181.2, 154.6
(d, J = 253.3 Hz), 147.5 (d, J = 3.9 Hz), 143.8, 141.6, 138.1 (d, J =
25.6 Hz), 131.3, 130.3, 130.1, 126.1, 118.1, 109.4, 50.9, 47.5 (d, J = 5.0
Hz), 41.5, 38.7, 32.3, 31.8, 26.6; LC−MS (method C, ESI, m/z) tR =
1.69 min, 431 (M + H)+; ESI-HRMS calcd for C21H24FN4O3S (M +
H)+ 431.1548, found 431.1590.
8-(3-Bromo-5-fluoropyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]-
decan-2-one (59). 8-Benzyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one
(7.40 g, 98% pure) was dissolved in MeOH (34 mL), THF (17
mL), and acetic acid (8 mL). Pd/C 5% (54.1% H2O, 4.00 g) was
added, and the reaction mixture was stirred at rt under hydrogen for
16 h. The catalyst was then filtered off and the filtrate was evaporated
to dryness. The residue was triturated with diethyl ether/diethyl ether,
filtered and dried in vacuum to yield 6.16 g (97% yield) of 1-oxa-3,8-
diazaspiro[4.5]decan-2-one acetate 38 as a white solid which was used
directly in the next step. LC−MS (method B, ESI, m/z) tR = 0.39 min,
157 (M + H)+.
3-Bromo-4-chloro-5-fluoropyridine 57 (656 mg, 3.12 mmol) and 1-
oxa-3,8-diazaspiro[4.5]decan-2-one acetate 38 (1.34 g, 6.23 mmol)
were introduced in a microwave vial, and 1-methoxy-2-propanol (7.8
mL) and triethylamine (1.34 mL, 9.35 mmol) were added, and the
reaction mixture was stirred at 220 °C for 1 h under microwave
irradiation. The solvent was evaporated and the crude material was
purified by Biotage column chromatography (DCM/EtOH 98:2 to
95:5) to afford 8-(3-bromo-5-fluoropyridin-4-yl)-1-oxa-3,8-diaza-
spiro[4.5]decan-2-one 59 (380 mg, 37% yield) as a cream solid. 1H
NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.25 (d, J = 3.4 Hz, 1H),
6.20 (s, 1H), 3.58−3.50 (m, 2H), 3.42 (s, 2H), 3.31−3.24 (m, 2H),
2.12−2.06 (m, 2H), 1.99−1.92 (m, 2H); 19F NMR (500 MHz,
CDCl3) δ −135; LC−MS (method C, ESI, m/z) tR = 2.32 min, 330/




decan-2-one 59 (50 mg, 0.15 mmol), 1-methyl-5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide 14
(52 mg, 0.17 mmol), and Pd(dppf)Cl2·CH2Cl2 (6.2 mg, 7.6 μmol)
were loaded in a microwave vial, and acetonitrile (2.6 mL) and 0.5 M
sodium carbonate in water (424 μL, 0.212 mmol) were added. The
reaction mixture was stirred at 120 °C for 60 min. After evaporation of
the solvent, the crude material was purified by Biotage column
chromatography (DCM/EtOH 98:2 to 95:5) and by SCX-2 column
chromatography (loading with DCM/MeOH, elution with 1 N NH3
in MeOH) to afford 8-(3-fluoro-5-(1-methyl-2,2-dioxido-1,3-dihydro-
benzo[c]isothiazol-5-yl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-
2-one 63 (44 mg, 67% yield) as white solid. 1H NMR (500 MHz,
CDCl3) δ 8.26 (d, J = 4.1 Hz, 1H), 8.08 (s, 1H), 7.39 (dd, J = 8.2, 1.8
Hz, 1H), 7.30 (s, 1H), 6.81 (d, J = 8.2 Hz, 1H), 5.78 (s, 1H), 4.40 (s,
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2H), 3.32 (s, 2H), 3.28−3.16 (m, 5H), 3.06−3.03 (m, 2H), 1.92−1.81
(m, 2H), 1.72−1.64 (m, 2H); 19F NMR (500 MHz, CDCl3) δ −139;
13C NMR (126 MHz, CDCl3) δ 158.5, 154.4 (d, J = 253.0 Hz), 147.9
(d, J = 4.0 Hz), 143.1 (d, J = 7.4 Hz), 141.5, 138.0 (d, J = 25.5 Hz),
131.0, 130.3, 130.2, 125.6, 117.9, 109.3, 79.9, 51.3, 50.7, 47.0 (d, J =
4.6 Hz), 36.3, 26.5; LC−MS (method C, ESI, m/z) tR = 1.70 min, 433
(M + H)+; ESI-HRMS calcd for C20H22FN4O4S (M + H)
+ 431.1340,
found 433.1339.
4-Chloro-3,5-diiodopyridine (64). In a 3 L three-necked round-
bottom flask, 1,4-dihydropyridin-4-one (95% pure, 50 g, 0.50 mol) and
N-iodosuccinimide (97% pure, 232 g, 1.00 mmol) were suspended in
acetonitrile (1 L). The reaction mixture was heated under reflux for 3
h and then cooled with an ice bath, filtered and the filtrate washed with
acetonitrile (150 mL). The light yellow solid was dried at 60 °C under
reduced pressure for 15 h to obtain 3,5-diiodopyridin-4-ol36 (165 g,
95% yield) as a light yellow solid which was used directly in the next
step. LC−MS (method B, ESI, m/z) tR = 1.34 min, 347 (M + H)+.
In a 3 L three-necked round-bottom flask, 3,5-diiodopyridin-4-ol
(150 g, 432 mmol) was suspended in DMF (1 L). This mixture was
warmed to 70 °C, and phosphoryl chloride (39.7 mL, 432 mmol) was
slowly added in a dropwise manner (caution: slightly exothermic
reaction). After completion of the addition of phosphoryl chloride, the
reaction mixture was then heated to 95 °C for 30 min. The dark brown
mixture was cooled to rt and slowly poured into 6 L of ice−water. A
beige precipitate formed. NaHCO3 was added slowly until no more
gas formation was observed. The solid was filtered and washed with
water (2 L). The residue was suspended in acetonitrile (800 mL) and
filtered again. The residue was washed with acetonitrile (100 mL) and
dried at 60 °C under reduced pressure for 15 h to give 4-chloro-3,5-
diiodopyridine37 64 as a yellow solid, which was used without further
purification (142 g, 95% pure, 85% corrected yield). LC−MS (method
B, ESI, m/z) tR = 3.06 min, 366/368 (M + H)
+.
8-(3,5-Diiodopyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-
one (66). In a 50 mL round-bottom flask, 4-chloro-3,5-diiodopyridine
64 (500 mg, 1.37 mmol) and 1-oxa-3,8-diazaspiro[4.5]decan-2-one
acetate 38 (448 mg, 2.05 mmol) were suspended in NMP (10 mL)
and triethylamine (570 μL, 4.11 mmol). The reaction mixture was
stirred at 240 °C for 3 h and then cooled and poured into water (150
mL). The resulting precipitate was filtered and washed with water (20
mL). The solid was dissolved in DCM (150 mL), the solution was
dried over Na2SO4, filtered, and concentrated to dryness. The crude
residue was purified by flash column chromatography (Companion,
DCM/MeOH 100:0 to 90:10) to give 8-(3,5-diiodopyridin-4-yl)-1-
oxa-3,8-diazaspiro[4.5]decan-2-one (196 mg, 30% yield) 66 as a light
brown solid which was used directly in the next step. LC−MS
(method B, ESI, m/z) tR = 2.26 min, 486 (M + H)
+.
8-(3-Iodo-5-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diaza-
spiro[4.5]decan-2-one (68). Into a 10 mL Schlenck, silver(I)
fluoride (57 mg, 0.45 mmol) was loaded and DMF (3 mL) and
(trifluoromethyl)trimethylsilane (81 μL, 0.54 mmol) were added at rt,
and the resulting brown suspension was stirred for 15 min at rt. Then
finely powdered copper (43 mg, 0.67 mmol) was added and the
resulting dark red suspension was stirred for 1.5h at rt. The reaction
mixture turned green, and a silver precipitate formed on the vessel
wall. 8-(3,5-Diiodopyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
66 (196 mg, 0.403 mmol) was added, and the suspension was stirred
at 90 °C for 3 h. The green suspension was diluted with DMF (10
mL) and filtered over Celite. The filtrate was evaporated to dryness.
The crude residue was dissolved in DCM (10 mL) and treated with
diethyl ether (35 mL). The resulting light brown precipitate was
filtered and washed with diethyl ether (10 mL), The filtrate was
evaporated to dryness to yield in 8-(3-iodo-5-trifluoromethylpyridin-4-
yl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 68 as a yellow oil (78 mg,
71% pure, 32% corrected yield) which was used directly in the next
step. LC−MS (method B, ESI, m/z) tR = 2.45 min, 428 (M + H)+.
8 - ( 3 - ( 4 - ( 1 -Me t h y l - 1H - p y r a z o l - 4 - y l ) p h en y l ) - 5 -
(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-
2-one 2,2,2-Trifluoroacetate (72). To 1-methyl-4-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole27 37 (126
mg, 0.390 mmol) and Pd(dppf)Cl2·CH2Cl2 (5 mg, 0.01 mmol) was
added a solution of 8-(3-iodo-5-(trifluoromethyl)pyridin-4-yl)-1-oxa-
3,8-diazaspiro[4.5]decan-2-one 68 (71% pure, 78 mg, 0.13 mmol) in
acetonitrile (4 mL) and 0.5 M sodium carbonate solution (780 μL,
0.390 mmol). The reaction mixture was stirred at 120 °C for 1 h under
microwave irradiation and diluted with acetonitrile (5 mL), filtered
and the filtrate concentrated. The crude product was purified by
preparative HPLC (method A, 20 min gradient elution from 2:98 to
25:75 acetonitrile/water to give 8-(3-(4-(1-methyl-1H-pyrazol-4-yl)-
phenyl)-5-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]-
decan-2-one 2,2,2-trifluoroacetate 72 (18 mg, 24% yield) as a colorless
solid. 1H NMR (500 MHz, DMSO-d6) δ 8.82 (s, 1H), 8.53 (s, 1H),
8.24 (d, J = 0.8 Hz, 1H), 7.96 (d, J = 0.8 Hz, 1H), 7.71 (d, J = 8.2 Hz,
2H), 7.45 (s, 1H), 7.40 (d, J = 8.2 Hz, 2H), 3.88 (s, 3H), 3.13 (s, 2H),
2.96−2.84 (m, 4H), 1.69−1.56 (m, 4H); 19F NMR (500 MHz,
DMSO-d6, TFA salt) δ −74.5; 13C NMR (126 MHz, DMSO-d6, free
base) δ 157.7, 155.9, 155.3, 147.7 (d, J = 7.0 Hz), 136.5, 136.2, 134.1,
132.5, 130.0, 128.2, 124.9, 124.0 (q, J = 273 Hz), 121.3, 78.5, 50.0,
48.2, 38.8, 35.5; LC−MS (method C, ESI, m/z) tR = 2.64 min, 458 (M
+ H)+; ESI-HRMS calcd for C23H23F3N5O2 (M + H)
+ 458.1798,
found 458.1785.
Preparation of Compounds in Table 5, exemplified by
Compounds 86, 92, and 95. 5-Bromo-3,4-dichloropyridin-2-
amine (73). N-Bromosuccinimide (10.9 g, 61.3 mmol) was added to a
solution of 4-chloro-2-aminopyridine (7.50 g, 58.3 mmol) in dry
acetonitrile (130 mL) at rt under a nitrogen atmosphere. The yellow
solution was stirred for 3 h before the mixture was concentrated in
vacuo. The resulting crude product was purified by Biotage column
chromatography (cyclohexane/EtOAc 5:1 to 1:1) to give 5-bromo-4-
chloropyridin-2-amine38 as a yellow solid (10.0 g, 83% yield). 1H
NMR (500 MHz, CDCl3) δ 8.16 (s, 1H), 6.62 (s, 1H), 4.57 (s, 2H);
LC−MS (method C, ESI, m/z) tR = 2.04 min, 207/209/211 (M +
H)+.
N-Chlorosuccinimide (6.11 g, 45.8 mmol) was added portionwise
to a solution of 5-bromo-4-chloropyridin-2-amine (10.0 g, 48.2 mmol)
in dry acetonitrile (180 mL) at rt under a nitrogen atmosphere. The
reaction mixture was heated to 95 °C for 3 h and then cooled to rt.
The resultant solid was filtered off and washed with acetonitrile to give
the desired compound as a light brown solid. The filtrate was
concentrated to 50 mL, and the resulting precipitate was filtered and
the resultant solid collected. The two batches of solid material were
combined and recrystallized from hot acetonitrile to give two batches
of 5-bromo-3,4-dichloropyridin-2-amine 73 (P1, 6.8 g; P2, 2.0 g; 75%
yield) which were used in the next step without further purification. 1H
NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 5.06 (s, 2H); LC−MS
(method C, ESI, m/z) tR = 2.93 min, 241/243/245 (M + H)
+.
5-Bromo-3,4-dichloro-N,N-bis(4-methoxybenzyl)pyridin-2-
amine (81). A solution of 5-bromo-3,4-dichloropyridin-2-amine 73
(2.37 g, 4.91 mmol) in dry DMF (50 mL) at 0 °C was treated
portionwise with sodium hydride (60% in mineral oil) (0.775 g, 18.6
mmol) and the mixture stirred at 0 °C for 15 min before a solution of
p-methoxybenzyl chloride (2.10 mL, 15.5 mmol) in dry DMF (1 mL)
was added. The mixture was stirred at rt for 2 h before sat. NH4Cl
solution and EtOAc were added. The aqueous layer was extracted
three times with EtOAc. The combined organic layers were dried over
MgSO4, filtered, and concentrated in vacuo. The resulting brown
residue was purified by Biotage column chromatography (cyclo-
hexane/DCM 100:0 to 75:25) to give 5-bromo-3,4-dichloro-N,N-
bis(4-methoxybenzyl)pyridin-2-amine 81 (2.4 g, 80% yield) as a
colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.26 (s, 1H), 7.20 (d, J =
8.6 Hz, 4H), 6.85 (d, J = 8.6 Hz, 4H), 4.42 (s, 4H), 3.81 (s, 6H); LC−




chloro-N,N-bis(4-methoxybenzyl)pyridin-2-amine 81 (5.00 g, 10.4
mmol), 8-boc-2,8-diaza-spiro-[4.5]decan-1-one (2.64 g, 10.4 mmol),
and potassium fluoride (1.21 g, 20.7 mmol) were loaded in a
microwave vial. Triethylamine (4.00 mL, 31.1 mmol) and NMP (25
mL) were added, and the light brown solution was degassed with
argon. The reaction mixture was stirred at 220 °C for 1 h under
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microwave irradiation. After the addition of water, the aqueous layer
was extracted twice with EtOAc and the organic layer was washed with
water, dried over MgSO4, and concentrated under vacuum. The
resulting brown oil was purified by Biotage column chromatography
(DCM/EtOH, 97:3 to 90:10) to give 8-(2-(bis(4-methoxybenzyl)-
amino)-5-bromo-3-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
82 (3.0 g, 54% yield) as a light brown solid. 1H NMR (500 MHz,
CDCl3) δ 8.15 (br s, 1H), 7.19 (d, J = 8.7 Hz, 4H), 6.84 (d, J = 8.7 Hz,
4H), 5.62 (s, 1H), 4.38 (s, 4H), 3.80 (s, 6H), 3.42−3.32 (m, 6H),
2.25−2.15 (m, 4H), 1.68−1.46 (m, 2H); LC−MS (method C, ESI, m/





pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 82 (203 mg, 0.339
mmol) and 2-methyl-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)-1H-pyrazol-1-yl)propan-2-ol 9 (73% pure, 190 mg, 0.407
mmol) were dissolved in acetonitrile (5 mL). 0.5 M aqueous sodium
carbonate (1.40 mL, 0.678 mmol) and Pd(dppf)Cl2·CH2Cl2 (25 mg,
0.034 mmol) were added. The reaction mixture was stirred at 120 °C
for 1 h under microwave irradiation, and the solvent was evaporated.
The crude residue was purified by flash chromatography (n-heptane/
EtOAc, gradient and then with DCM/MeOH, gradient) to give 8-(2-
(bis(4-methoxybenzyl)amino)-3-chloro-5-(4-(1-(2-hydroxy-2-methyl-
propyl)-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]-
decan-1-one (81 mg, 60% pure, 19% corrected yield) as a light-brown
solid which was used directly in the next step. LC−MS (method A,




[4.5]decan-1-one (60% pure, 81 mg, 0.066 mmol) was dissolved in
TFA (1 mL) and stirred at rt overnight. The crude mixture was
concentrated, and the residue was treated with 1 N NaOH. The
mixture was extracted with EtOAc, and the organic layer was dried
over Na2SO4, filtered, and concentrated. The crude product was
dissolved in acetonitrile, and the resultant solid precipitate was filtered
and dried in vacuo to afford 8-(2-amino-3-chloro-5-(4-(1-(2-hydroxy-
2-methylpropyl)-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro-
[4.5]decan-1-one 86 (31 mg, 94% yield) as a beige solid. 1H NMR
(500 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.91 (s, 1H), 7.64 (s, 1H), 7.62
(d, J = 8.2 Hz, 2H), 7.51 (s, 1H), 7.23 (d, J = 8.2 Hz, 2H), 6.13 (s,
2H), 4.75 (s, 1H), 4.04 (s, 2H), 3.10 (t, J = 6.8 Hz, 2H), 3.01−2.93
(m, 2H), 2.74−2.61 (m, 2H), 1.82 (t, J = 6.8 Hz, 2H), 1.76−1.65 (m,
2H), 1.25−1.18 (m, 2H), 1.10 (s, 6H); 13C NMR (126 MHz, DMSO-
d6) δ 180.0, 156.3, 153.3, 147.7, 135.8, 135.7, 131.1, 129.6, 128.1,
124.7, 123.6, 121.1, 108.6, 69.3, 62.2, 47.4, 41.4, 37.8, 31.8, 30.4, 27.3;
LC−MS (method C, ESI, m/z) tR = 1.99 min, 495/497 (M + H)+;
ESI-HRMS calcd for C26H32
35ClN6O2 (M + H)
+ 495.2270, found
495.2256.
4,5-Dichloro-3-fluoropyridin-2-amine (74). To a solution of
LDA (2 M, 7.97 mL, 15.9 mmol) in THF (31 mL) at −78 °C was
added 5-chloro-3-fluoropyridin-2-amine (934 mg, 6.37 mmol) in
solution in THF (9 mL). After 50 min at −78 °C, hexachloroethane
(1.44 mL, 12.8 mmol) in THF (9 mL) was added. The reaction
mixture was stirred for 40 min and then quenched with NH4Cl and
extracted with DCM. The crude material was purified by Biotage
column chromatography (DCM 100%) to afford 4,5-dichloro-3-
fluoropyridin-2-amine 74 (950 mg, 82% yield) as a cream solid. 1H
NMR (500 MHz, CDCl3) δ 7.92 (d, J = 1.0 Hz, 1H), 4.74 (s, 2H);
19F
NMR (500 MHz, CDCl3) δ −137; LC−MS (method C, ESI, m/z) tR
= 2.66 min, 181/183/185 (M + H)+.
8-(2-Amino-5-chloro-3-fluoropyridin-4-yl)-2,8-diazaspiro-
[4.5]decan-1-one (77). 4,5-Dichloro-3-fluoropyridin-2-amine 74
(100 mg, 0.553 mmol) and tert-butyl 1-oxo-2,8-diazaspiro[4.5]-
decane-8-carboxylate (211 mg, 0.829 mmol) were introduced in a
microwave vial, and NMP (1.4 mL) and triethylamine (233 μL, 1.66
mmol) were added. The reaction mixture was stirred for 2 × 1 h at 220
°C under microwave irradiation. The reaction mixture was
concentrated and the crude material was purified by Biotage column
chromatography (DCM/EtOH 98:2 to 94:6) to afford 8-(2-amino-5-
chloro-3-fluoropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 77 (105
mg, 64% yield) as a cream solid. 1H NMR (500 MHz, DMSO-d6) δ
7.67 (s, 1H), 7.59 (s, 1H), 6.17 (s, 2H), 3.35−3.27 (m, 2H), 3.19 (t, J
= 6.8 Hz, 2H), 3.12−3.05 (m, 2H), 2.01 (t, J = 6.8 Hz, 2H), 1.79 (td, J
= 12.4, 4.2 Hz, 2H), 1.44−1.38 (m, 2H); 19F NMR (500 MHz,
DMSO-d6) δ −149; LC−MS (method C, ESI, m/z) tR = 1.73 min,




[4.5]decan-1-one 7 (20 mg, 0.067 mmol), 1-methyl-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydrobenzo[c]isothiazole
2,2-dioxide 14 (27 mg, 0.087 mmol), and PdCl2(Pcy3)2 (2.5 mg, 3.4
μmol) were loaded in a microwave vial. Acetonitrile (1.1 mL) and 0.5
M sodium carbonate in water (187 μL, 0.0940 mmol) were added, and
the reaction mixture was stirred at 150 °C for 30 min under microwave
irradiation. After evaporation of the solvent, the crude material was
purified by Biotage column chromatography (DCM/EtOH 98:2 to
90:10) to afford 8-(2-amino-3-fluoro-5-(1-methyl-2,2-dioxido-1,3-
dihydrobenzo[c]isothiazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-
1-one 92 (17 mg, 57% yield) as a cream solid. 1H NMR (500 MHz,
DMSO-d6) δ 7.54 (s, 1H), 7.48 (s, 1H), 7.45 (d, J = 1.8 Hz, 1H), 7.41
(dd, J = 8.3, 1.8 Hz, 1H), 6.97 (d, J = 8.3 Hz, 1H), 6.02 (s, 2H), 4.67
(s, 2H), 3.12 (t, J = 6.8 Hz, 2H), 3.08−3.01 (m, 2H), 3.06 (s, 3H),
2.89 (t, J = 12.2 Hz, 2H), 1.91 (t, J = 6.8 Hz, 2H), 1.61−1.52 (m, 2H),
1.21−1.15 (m, 2H); 19F NMR (500 MHz, DMSO-d6) δ −153; 13C
NMR (126 MHz, DMSO-d6) δ 180.5, 150.4 (d, J = 12.8 Hz), 143.9 (d,
J = 5.4 Hz), 142.7 (d, J = 4.3 Hz), 141.1 (d, J = 247 Hz), 140.6, 131.3,
129.5, 126.4, 121.8, 118.7, 109.8, 50.6, 47.5 (d, J = 4.6 Hz), 41.6, 38.3,
32.1, 31.1, 26.6; LC−MS (method C, ESI, m/z) tR = 1.73 min, 446 (M




3-(Trifluoromethyl)pyridin-2-amine (35.0 g, 0.210 mol) in DMF
(350 mL) was cooled to 0−5 °C under a nitrogen atmosphere. N-
Bromosuccinimide (38.8 g, 0.210 mol) was added portionwise, and the
mixture was stirred at rt for 1 h. The reaction mixture was
concentrated, and the light brown viscous liquid residue was triturated
with ice-cold water (200 mL). The precipitate was filtered and dried to
afford 5-bromo-3-(trifluoromethyl)pyridin-2-amine39 (45.0 g, 86%
yield) as an off-white solid that was used directly in the next step.
To a stirred solution of 5-bromo-3-(trifluoromethyl)pyridin-2-
amine (25.0 g, 0.100 mol) in THF (250 mL) was added sodium
hydride (60% in mineral oil, 7.35 g, 0.180 mol) portionwise at 0−5 °C
under a nitrogen atmosphere; the reaction mixture was stirred for 1 h
at 0−5 °C. A solution of di-tert-butyl dicarbonate (25.8 mL, 0.110
mol) in THF (50 mL) was added dropwise at 0−5 °C, and stirring was
continued for 3 h. Since the reaction was incomplete, sodium hydride
(60% in mineral oil, 4.08 g, 0.100 mol) was added portionwise at 0−5
°C and stirring continued for 1 h. A solution of di-tert-butyl
dicarbonate (12 mL, 0.050 mol) in THF (20 mL) was added
dropwise, and the reaction mixture was stirred for an additional 2 h at
0−5 °C. The mixture was poured onto ice cold water (250 mL) and
extracted with ethyl acetate (3 × 150 mL). The combined organic
layers were washed with brine (100 mL), dried over Na2SO4, and
concentrated under reduced pressure to afford a brown viscous solid.
The residue was purified by column chromatography (petroleum
ether/EtOAc 100:0 to 94:6) to give tert-butyl (5-bromo-3-
(trifluoromethyl)pyridin-2-yl)carbamate (30 g, 74% yield) as an off-
white solid that was taken to the next step without further purification.
To a stirred solution of diisoproylamine (13 mL, 0.090 mol) in
THF (220 mL) cooled to −70 °C under nitrogen atmosphere was
added n-butyllithium (1.6 M solution in hexane, 54 mL, 0.090 mol)
dropwise over a period 0.5 h, and the mixture was stirred for additional
30 min at the same temperature. The mixture was slowly warmed to
−10 °C and stirred for 20 min. After cooling to −70 °C a solution of
(tert-butyl (5-bromo-3-(trifluoromethyl)pyridin-2-yl)carbamate (22 g,
0.040 mol) in THF (100 mL) was added dropwise over a period 20
min at −10 °C. The mixture was stirred for 30 min at −70 °C, then a
solution of 1,1,1,2,2,2-hexachloroethane (21 g, 0.090 mol) in THF
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(100 mL) was added dropwise over a period of 30 min and the
reaction mixture stirred for a 1 h at the same temperature. The mixture
was slowly warmed to rt and stirred for additional 20 min, poured onto
ice-cold water (200 mL), and extracted with EtOAc (3 × 200 mL).
The combined organic layers were washed with brine (100 mL), dried
over Na2SO4, and concentrated to give the crude product as a brown
viscous solid. The crude product was purified by column
chromatography (petroleum ether/EtOAc 95:5 to 90:10) to afford
tert-butyl (5-bromo-4-chloro-3-(trifluoromethyl)pyridin-2-yl)-
carbamate (9.5 g, 62% yield) as an off-white solid which was used
directly in the next step.
tert-Butyl (5-bromo-4-chloro-3-(trifluoromethyl)pyridin-2-yl)-
carbamate (9.5 g, 0.020 mol) in 1,4-dioxane (48 mL) was cooled to
0−5 °C. HCl in 1,4-dioxane (4 mol/L, 95 mL) was added dropwise
over 20 min. The reaction mixture was stirred at rt for 4 h and then
evaporated to give an off-white solid. The residue was taken up in
aqueous 10% NaHCO3. The resulting precipitate was filtered off and
dried in vacuo. The crude product was purified by column
chromatography (petroleum ether/EtOAc 100:0 to 90:10) to afford
5-bromo-4-chloro-3-(trifluoromethyl)pyridin-2-amine 75 (4.85 g, 70%
yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s,
1H), 6.95 (s, 2H); LC−MS (method E, ESI, m/z) tR = 4.38 min, 275/
277/279 (M + H)+.
8-(2-Amino-5-bromo-3-(trifluoromethyl)pyridin-4-yl)-1-oxa-
3,8-diazaspiro[4.5]decan-2-one (80). 5-Bromo-4-chloro-3-
(trifluoromethyl)pyridin-2-amine 75 (300 mg, 1.09 mmol) and 1-
oxa-3,8-diazaspiro[4.5]decan-2-one 38 (340 mg, 2.18 mmol) were
dissolved in NMP (3 mL), and triethylamine (0.453 mL, 3.27 mmol)
was added. The reaction mixture was stirred for 2 h at 220 °C under
microwave irradiation. The resultant black reaction mixture was
poured into 60 mL of water. The brown precipitate was filtered,
washed with water and diethyl ether, and then dried to give 8-(2-
amino-5-bromo-3-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diaza-
spiro[4.5]decan-2-one 80 (280 mg, 89% pure, 58% corrected yield) as
a pale brown solid which was used directly in the next step. LC−MS




2-one 2,2,2-Trifluoroacetate (95). 8-(2-Amino-5-bromo-3-
(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
80 (89% pure, 140 mg, 0.315 mmol) was suspended in acetonitrile (10
mL). 1-Methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
phenyl)-1H-pyrazole 37 (81% pure, 166 mg, 0.473 mmol), 0.5 M
aqueous sodium carbonate (1.26 mL, 0.631 mmol), and Pd(dppf)Cl2·
CH2Cl2 (13 mg, 0.016 mmol) were added. The reaction mixture was
stirred at 120 °C for 1 h under microwave irradiation. After addition of
EtOAc, the mixture was filtered and the filtrate was concentrated. The
brown oily residue was purified by preparative HPLC (method A,
gradient elution from 2:98 to 30:70 acetonitrile/water in 20 min) to
afford 8-(2-amino-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-
(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
2,2,2-trifluoroacetate 95 (46 mg, 25% yield) as a white fluffy solid. 1H
NMR (500 MHz, DMSO-d6) δ 8.20 (d, J = 0.8 Hz, 1H), 7.92 (d, J =
0.8 Hz, 1H), 7.76 (s, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.48 (s, 1H), 7.37
(d, J = 8.2 Hz, 2H), 3.87 (s, 3H), 3.13 (s, 2H), 3.12−3.01 (m, 4H),
1.61−1.45 (m, 4H); 13C NMR (126 MHz, DMSO-d6) δ 160.8, 157.6,
154.2, 144.0, 136.2, 133.1, 132.3, 130.1, 128.1, 124.9, 124.0, 121.3,
78.1, 49.8, 48.1, 38.7, 34.5 (1 Cq not observed); LC−MS (method C,
ESI, m/z) tR = 2.05 min, 473 (M + H)
+; ESI-HRMS calcd for
C23H24F3N6O2 (M + H)
+ 473.1907, found 473.1893.
Preparation of Compounds in Table 7, Exemplified by
Compounds 100, 101, and 102. 3-(Methylamino)-1H-indazol-
6-yl)boronic Acid (97). 6-Bromo-1H-indazol-3-amine (95% pure,
1.00 g, 4.48 mmol) was dissolved in pyridine (20 mL) and the mixture
cooled to 0 °C; phenyl chloroformate (0.620 mL, 4.93 mmol) was
added dropwise. and the reaction mixture was stirred at 0 °C for 4 h.
After addition of DCM (50 mL) and water (50 mL), the layers were
separated and the organic layer was washed with brine, dried over
Na2SO4, and evaporated to dryness. The residue was purified by flash
chromatography (n-heptane/EtOAc, gradient) and by preparative
HPLC (method A, gradient elution from 0:100 to 30:70 over 3 min
and to 60:40 over 17 min acetonitrile/water) to give first the desired
phenyl (6-bromo-1H-indazol-3-yl)carbamate40 (54 mg, 3% yield) as a
white solid, which was used directly in the next step, and second
undesired phenyl 3-amino-6-bromo-1H-indazole-1-carboxylate (346
mg) as a white solid. LC−MS (method B, ESI, m/z) tR = 2.62 min,
332/334 (M + H)+.
Phenyl (6-bromo-1H-indazol-3-yl)carbamate (54 mg, 0.16 mmol)
was dissolved in THF (3 mL), and lithium aluminum hydride solution
1.0 M in THF (325 μL, 0.330 mmol) was added dropwise. The
solution turned from colorless to yellow. The mixture was stirred at rt
for 2 h and then diluted with water (2 mL) and THF (8 mL). The
suspension was filtered over Celite and the mother liquor was
evaporated to dryness to give 6-bromo-N-methyl-1H-indazol-3-
amine40 (41 mg, 89% pure, 99% corrected yield) as a pale brown
solid which was used directly in the next step. LC−MS (method B,
ESI, m/z) tR = 1.95 min, 226/228 (M + H)
+.
6-Bromo-N-methyl-1H-indazol-3-amine (89% pure, 41 mg, 0.16
mmol), bis(pinacolato)diboron (82 mg, 0.32 mmol), potassium
acetate (48 mg, 0.48 mmol), and Pd(dppf)Cl2·CH2Cl2 (13 mg,
0.020 mmol) were loaded in a microwave vial, and acetonitrile was
added (4 mL). The reaction mixture was stirred for 1 h at 120 °C
under microwave irradiation and then diluted with acetonitrile (10
mL), filtered and the filtrate evaporated to dryness. The crude residue
97 (230 mg, 13% pure, 100% corrected yield) was used in the next
step without purification. LC−MS (method B, ESI, m/z) tR = 1.79
min, 191/192 (M + H)+.
8-(3-Chloro-5-(3-(methylamino)-1H-indazol-6-yl)pyridin-4-
yl)-2,8-diazaspiro[4.5]decan-1-one (100). 8-(3-Bromo-5-chloro-
pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one27 8 (70.3 mg, 0.20
mmol), (3-(methylamino)-1H-indazol-6-yl)boronic acid 97 (13%
pure, 230 mg, 0.160 mmol) were loaded in a microwave vial, and
acetonitrile (4 mL), 0.5 M aqueous sodium carbonate (1.23 mL, 0.610
mmol) and Pd(dppf)Cl2·CH2Cl2 (8 mg, 0.01 mmol) were added. The
reaction mixture was stirred for 1 h at 120 °C under microwave
irradiation. After dilution with acetonitrile (5 mL), the mixture was
filtered and the filtrate was concentrated. The crude product was
purified by preparative HPLC (method A, 20 min gradient elution
from 2:98 to 20:80 acetonitrile/water) to give 8-(3-chloro-5-(3-
(methylamino)-1H-indazol-6-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]-
decan-1-one 100 (13 mg, 12% yield) as a white solid. 1H NMR (500
MHz, CD3OD) δ 8.56 (s, 1H), 8.28 (s, 1H), 7.89 (dd, J = 8.4, 0.8 Hz,
1H), 7.41−7.37 (m, 1H), 7.07 (dd, J = 8.4, 1.4 Hz, 1H), 3.41−3.35
(m, 2H), 3.27 (t, J = 6.9 Hz, 2H), 3.06 (s, 3H), 2.97−2.89 (m, 2H),
2.00 (t, J = 6.9 Hz, 2H), 1.92−1.84 (m, 2H), 1.41 (d, J = 13.3 Hz,
2H); LC−MS (method C, ESI, m/z) tR = 1.74 min, 411/413 (M +
H)+; ESI-HRMS calcd for C21H24





6-Bromo-1-methyl-1H-indazol-3-amine (500 mg, 2.21 mmol) and
N,N-dimethylpyridin-4-amine (54 mg, 0.44 mmol) were dissolved in
DCM (15 mL). Triethylamine (1.74 mL, 13.3 mmol) and di-tert-butyl
dicarbonate (1.42 mL, 6.64 mmol) were were added, and the reaction
solution was stirred overnight at rt. After addition of water and DCM,
the layers were separated and the aqueous layer was extracted with
DCM. The organic layer was washed with water, dried, filtered, and
evaporated to dryness. The brown solid was purified by flash-
chromatography (Companion, n-heptane/EtOAc gradient) to give
tert-butyl N-(6-bromo-1-methyl-indazol-3-yl)-N-tert-butoxycarbonyl-
carbamate (150 mg, 16% yield) as a colorless solid which was used
directly in the next step. LC−MS (method B, ESI, m/z) tR = 3.29 min,
448/450 (M + Na)+.
tert-Butyl N-(6-bromo-1-methylindazol-3-yl)-N-tert-butoxycarbonyl-
carbamate (150 mg, 0.352 mmol) was dissolved in THF (5 mL).
Bis(pinacolato)diboron (179 mg, 0.704 mmol), potassium acetate
(104 mg, 1.06 mmol), and Pd(dppf)Cl2·CH2Cl2 (29 mg, 0.035 mmol)
were added, and the red reaction mixture was stirred overnight at 70
°C. The resultant black reaction mixture was treated with EtOAc,
filtered and the filtrate evaporated under vacuum. The dark brown
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residue was purified by flash chromatography (Companion, heptane/
DCM gradient) to give a mixture of [3-[bis(tert-butoxycarbonyl)-
amino]-1-methyl-indazol-6-yl]boronic acid and tert-butyl N-tert-
butoxycarbonyl-N-[1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)indazol-3-yl]carbamate (2:3 ratio, 182 mg, quant) as a pale
yellow solid 98 which was used directly in the next step. LC−MS
(method B, ESI, m/z) tR = 2.59 min, 413/414 (M + Na)
+ and tR =




one27 8 (84.4 mg, 0.25 mmol) was suspended in acetonitrile (2
mL). A mixture of tert-butyl N-tert-butoxycarbonyl-N-[1-methyl-6-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-3-yl]carbamate
and [3-[bis(tert-butoxycarbonyl)amino]-1-methyl-indazol-6-yl]boronic
acid 98 (3:2 ratio, 174 mg, ∼0.368 mmol), 0.5 M aqueous sodium
carbonate (982 uL, 0.491 mmol), and Pd(dppf)Cl2·CH2Cl2 (18 mg,
0.025 mmol) were added. The reaction mixture was stirred for 1 h at
120 °C. After addition of EtOAc, the mixture was filtered and the
filtrate was concentrated. The brown residue was purified by flash
chromatography (Companion, DCM/MeOH gradient) to give tert-
butyl (6-(5-chloro-4-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)pyridin-3-
yl)-1-methyl-1H-indazol-3-yl)carbamate (47 mg, 71% pure, 27%
corrected yield) as a colorless solid which was used directly in the
next step. LC−MS (method B, ESI, m/z) tR = 2.19 min, 511/513 (M
+ H)+.
tert-Butyl (6-(5-chloro-4-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-
pyridin-3-yl)-1-methyl-1H-indazol-3-yl)carbamate (71% pure, 47 mg,
0.066 mmol) was dissolved in 5 N hydrogen chloride in dioxane (5
mL) and MeOH (1 mL). The pale brown solution was stirred at rt for
4 h, and the solvents were evaporated. The residue was purified by
preparative HPLC (method A, 20 min gradient elution from 2:98 to
25:75 acetonitrile/water) to give 8-(3-(3-amino-1-methyl-1H-indazol-
6-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 2,2,2-tri-
fluoroacetate 101 (15 mg, 43% yield) as a yellow solid. 1H NMR
(500 MHz, CD3OD) δ 8.66 (s, 1H), 8.35 (s, 1H), 7.88 (d, J = 8.4 Hz,
1H), 7.47 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 3.55−3.47
(m, 2H), 3.27 (t, J = 6.9 Hz, 2H), 3.02−2.95 (m, 2H), 2.01 (t, J = 6.9
Hz, 2H), 1.95−1.87 (m, 2H), 1.50−1.42 (m, 2H); 13C NMR (126
MHz, CD3OD) δ 183.1, 159.7, 148.3, 144.4, 143.3, 143.1, 136.6, 134.7,
127.8, 122.5, 121.2, 115.5, 110.6, 49.8, 43.1, 39.7, 35.1, 33.4, 32.6;
LC−MS (method C, ESI, m/z) tR = 1.86 min, 411/413 (M + H)+;
ESI-HRMS calcd for C21H24




2-yl)-1H-indazol-3-amine (99). 4-Bromo-2-fluorobenzonitrile (1.0
g, 5.0 mmol) was dissolved in ethanol (11 mL), and methylhydrazine
(0.756 mL, 14.4 mmol) was added. The reaction mixture was stirred
under microwave irradiation at 120 °C for 50 min. The reaction was
quenched with water, and the product was extracted with EtOAc three
times. The combined organic layers were dried over MgSO4 and
concentrated to give 6-bromo-1-methyl-1H-indazol-3-amine41 (940
mg, 83% yield) as a brown solid. 1H NMR (500 MHz, CDCl3) δ 7.47
(dd, J = 8.7, 0.7 Hz, 1H), 7.38 (dd, J = 1.5, 0.7 Hz, 1H), 7.13 (dd, J =
8.7, 1.5 Hz, 1H), 3.80 (s, 3H); LC−MS (method C, ESI, m/z) tR =
2.50 min, 226/228 (M + H)+.
To 6-bromo-1-methyl-1H-indazol-3-amine (736 mg, 3.26 mmol) in
formic acid (3.7 mL, 98 mmol) was added formaldehyde 37% in water
(897 μL, 32.6 mmol). The reaction mixture was heated at 100 °C for 2
h and concentrated. The crude material was purified by Biotage
column chromatography (cyclohexane/EtOAc 95:5 to 82:18) to afford
6-bromo-N,N,1-trimethyl-1H-indazol-3-amine (85 mg, 10% yield) as a
brown solid. 1H NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 8.7, 0.6 Hz,
1H), 7.37 (dd, J = 1.5, 0.6 Hz, 1H), 7.06 (dd, J = 8.7, 1.5 Hz, 1H), 3.82
(s, 3H), 3.07 (s, 6H); LC−MS (method C, ESI, m/z) tR = 3.11 min,
254/256 (M + H)+.
6-Bromo-N,N,1-trimethyl-1H-indazol-3-amine (100 mg, 0.394
mmol), bis(pinacolato)diboron (150 mg, 0.590 mmol), potassium
acetate (116 mg, 1.18 mmol), and Pd(dppf)Cl2·CH2Cl2 (16 mg, 0.020
mmol) were loaded in a flask, and DME (2.8 mL) was added. The
reaction mixture was heated at 80 °C overnight and concentrated. The
crude material was purified by Biotage column chromatography
(cylohexane/EtOAc 95:5 to 70:30) to give N,N,1-trimethyl-6-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine 99 (100 mg,
84% yield). 1H NMR (500 MHz, CDCl3) δ 7.75 (dd, J = 8.1, 0.9 Hz,
1H), 7.72 (s, 1H), 7.39 (d, J = 8.1 Hz, 1H), 3.91 (s, 3H), 3.09 (s, 6H),





mg, 0.036 mmol), N,N,1-trimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1H-indazol-3-amine 99 (12 mg, 0.040 mmol), and
Pd(dppf)Cl2·CH2Cl2 (1.5 mg, 1.8 μmol) were loaded in a microwave
vial, and acetonitrile (624 μL) and 0.5 M sodium carbonate in water
(101 μL, 0.0510 mmol) were added. The reaction was stirred at 120
°C for 60 min under microwave irradiation. The solvent was
evaporated, and the crude material was purified by Biotage column
chromatography (DCM/EtOH 98:2 to 91:9) and then by preparative
HPLC (method B). Fractions were concentrated under vacuum and
the product was solubilized in DCM and filtered on a basic Isolute
flash NH2 column to afford 8-(3-chloro-5-(3-(dimethylamino)-1-
methyl-1H-indazol-6-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
102 (8 mg, 50% yield). 1H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H),
8.27 (s, 1H), 7.82 (dd, J = 8.4, 0.8 Hz, 1H), 7.13 (dd, J = 1.4, 0.8 Hz,
1H), 6.88 (dd, J = 8.4, 1.4 Hz, 1H), 5.68 (s, 1H), 3.92 (s, 3H), 3.28−
3.23 (m, 2H), 3.21−3.15 (m, 2H), 3.13 (s, 6H), 2.71 (t, J = 11.8 Hz,
2H), 2.00−1.90 (m, 4H), 1.36−1.29 (m, 2H); LC−MS (method C,
ESI, m/z) tR = 2.40 min, 439/441 (M + H)
+; ESI-HRMS calcd for
C23H28
35ClN6O (M + H)
+ 439.2008, found 439.2004.
Preparation of Compounds in Table 8, Exemplified by
Compound 109. 8-(2-Amino-3-chloro-5-(1-methyl-1H-indazol-
5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one (109). Into a
500 mL screw cap jar, 8-(2-(bis(4-methoxybenzyl)amino)-5-bromo-3-
chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 82 (82% pure, 13.4
g, 18.4 mmol), 1-methylindazole-5-boronic acid 39 (97% pure, 4.99 g,
27.5 mmol), and Pd(dppf)Cl2·CH2Cl2 (749 mg, 0.920 mmol) were
weighed in and suspended in acetonitrile (300 mL) and sodium
carbonate solution (0.5 M, 73.4 mL, 36.7 mmol). The reaction mixture
was stirred at 80 °C overnight. The mixture was diluted with
acetonitrile (200 mL), filtered, and evaporated to dryness. The crude
residue was purified by flash chromatography (DCM/MeOH,
gradient). The isolated product was suspended in acetonitrile (100
mL) and treated with diethyl ether (200 mL). The resultant beige
precipitate was filtered, washed with diethyl ether (100 mL), and dried
under vacuum. The mother liquor was evaporated to 50 mL volume
and treated with diethyl ether (100 mL). The resulting precipitate was
filtered, washed with diethyl ether (40 mL), and dried under vacuum.
The two batches of compound were combined to yield in 8-(2-(bis(4-
methoxybenzyl)amino)-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-
4-yl)-2,8-diazaspiro[4.5]decan-1-one (7.05 g, 59% yield) as a colorless
solid which was used directly in the next step. LC−MS (method B,
ESI, m/z) tR = 2.78 min, 651/653 (M + H)
+.
8-(2-(Bis(4-methoxybenzyl)amino)-3-chloro-5-(1-methyl-1H-inda-
zol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one (7.05 g, 10.8
mmol) was dissolved in trifluoroacetic acid (70 mL) and the reaction
mixture stirred at rt for 4 h. The solution was evaporated to dryness.
The crude residue was suspended in DCM and treated with diethyl
ether (350 mL). The white precipitate was filtered and washed with
diethyl ether (100 mL) and dried under vacuum overnight. The
residue was dissolved in DMSO (50 mL) and poured into sodium
carbonate solution (0.25 M, 500 mL). The resulting light yellow
precipitate was filtered, washed with water (150 mL), and dried at 70
°C under vacuum overnight to give 8-(2-amino-3-chloro-5-(1-methyl-
1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one 109
(3.34 g, 75% yield) as a light yellow solid. 1H NMR (500 MHz,
DMSO-d6) δ 8.05 (d, J = 1.0 Hz, 1H), 7.69−7.64 (m, 2H), 7.63−7.60
(m, 1H), 7.49 (s, 1H), 7.27 (dd, J = 8.6, 1.6 Hz, 1H), 6.10 (s, 2H),
4.07 (s, 3H), 3.07 (t, J = 6.7 Hz, 2H), 2.98−2.92 (m, 2H), 2.67−2.55
(m, 2H), 1.74 (t, J = 6.7 Hz, 2H), 1.71−1.61 (m, 2H), 1.16 (d, J = 12.6
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Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 180.0, 156.2, 153.5,
148.2, 138.7, 132.4, 130.6, 128.4, 124.2, 123.7, 120.3, 109.2, 108.8,
47.3, 41.4, 37.8, 35.5, 31.8, 30.3; LC−MS (method C, ESI, m/z) tR =
1.79 min, 411/413 (M + H)+. ESI-HRMS calcd for C21H24
35ClN6O
(M + H)+ 411.1695, found 411.1681.
Mouse, Rat, and Human Clint Determination. Microsomes
(final concentration 0.5 mg/mL), 50 mM phosphate buffer pH 7.4,
and compound (final concentration 1 μM) were added to the assay
plate and allowed to preincubate for 5 min at 37 °C. The reaction was
initiated by the addition of NADPH (final concentration 1.5 mM), and
the plate was shaken at 800 rpm at 37 °C. After 0, 5, 10, 20, and 30
min aliquots were taken and the reaction was stopped using cold
acetonitrile. The samples were centrifuged at 4000 rpm for 30 min at 4
°C and analyzed by LC−MS/MS. Four test compounds were pooled
for analysis. The in vitro intrinsic clearance was calculated from the
rate of compound disappearance.
Caco-2 Papp Determination. Caco-2 cells were maintained in
DMEM in an atmosphere of 8.5% CO2. For transport experiments
0.125 × 106 cells/well of were seeded on polycarbonate filter inserts
and allowed to grow and differentiate for 14 ± 1 days before the cell
monolayers were used for experiments. Drug transport experiments
were carried out using a cocktail approach in a four-dimensional
setting. Apparent permeability coefficients were determined for A→ B
and B→ A directions with and without the presence of cyclosporine A
as a transporter inhibitor. Up to five test items and reference
compounds were dissolved in Hank’s balanced salt solution at pH 7.4
to yield a final concentration of 1 μM. The assays were performed in
HBSS containing 25 mM HEPES (pH 7.4) in an atmosphere of 5%
CO2 at 37 °C. Prior to the study, the monolayers were washed in
prewarmed HBSS. At the start of the experiments prewarmed HBSS
containing the test items was added to the donor side of the
monolayer and HBSS without test items was added to the receiver
side. The plates were shaken at 150 rpm at 37 °C during the
experiment. After 2 h the Transwell insert containing the monolayer
was carefully removed and placed in a new plate and aliquots of both
the receiver and donor sides were taken and diluted with an equal
volume of acetonitrile containing the internal standard. The mixture
was centrifuged and supernatant analyzed by LC−MS/MS. The
apparent permeability coefficients (Papp) were calculated using the
formula: Papp = [Vrec/(A × C0,donor)](dCrec/dt) × 10
6 with dCrev/dt
being the change in concentration in the receiver compartment with
time, Vrec the volume of the sample in the receiver compartment,
C0,donor the concentration in the donor compartment at time 0, and A
the area of the compartment with the cells.
In Vivo Mouse PK In-Life Phase. Female NMRI mice (n = 5)
received either a single intravenous (bolus) injection or single oral
administration (by gavage) of the compound in a cocktail preparation.
Doses of 0.2 mg/kg (per compound, intravenous administration) and
0.5 mg/kg (per compound, perorally) were given as solutions in
DMSO/PEG 200/water. Consecutive blood samples were taken
retroorbitally under isofluorane inhalation from n = 3 animals per
route of administration after 0.1 (iv only), 0.25 (po only), 0.5, 1, 2, 4,
and 6 h and were further processed to obtain plasma. In addition, feces
of 2 mice per route of administration were collected over the time
interval from 0 to 24 h (pooled for analysis, no blood sampling).
In Vivo Rat PK In-Life Phase. Male Wistar rats (n = 6) received
either a single intravenous (bolus) injection or a single oral
administration (by gavage) of the compound in a cocktail preparation.
Doses of 0.2 mg/kg (pre compound, intravenous administration) and
0.5 mg/kg (per compound, perorally) were given as solutions in
DMSO/PEG 200/water. Consecutive blood samples were taken
sublingually under isofluorane inhalation from n = 3 animals per route
of administration after 0.1 (iv only), 0.25 (po only), 0.5, 1, 2, 4, and 6
h and were further processed to obtain plasma. In addition, feces and
urine of 3 rats per route of administration were collected over the time
interval from 0 to 24 h (pooled for analysis, no blood sampling).
In Vivo Dog PK In-Life Phase. Female Beagle dogs received
either a single intravenous (bolus) injection or an oral administration
(by gavage) of the compound in a cocktail preparation. Doses of 0.2
and 0.5 mg/kg were given intravenously and per orally as a solution in
DMSO/PEG 200/water, respectively. Consecutive blood samples
were taken by puncture of the vena cephalica from n = 2 animals per
route of administration (crossover design) predose and after 0.1 (only
(iv), 0.25 (only po), 0.5, 1, 2, 4, 6, 24, and 48 h and were further
processed to obtain plasma. The Institute of Cancer Research does not
use non-rodent species in research and, where this is deemed essential,
require ethical approval for use by organizations with whom we
collaborate. Pharmacokinetic analysis of compounds 6 and 109 in
dogs, necessary for prediction of human pharmacokinetics, was
approved by the ICR Ethics Committee. Studies were sponsored
and conducted in full compliance with national regulations at an
Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) accredited site of Merck Biopharma.
Bioanalytics. The concentrations of compound in plasma and
feces were quantified using an UPLC method with tandem mass
spectrometric detection (LC−MS/MS). The LC−MS system
consisted of a Waters Acquity UPLC coupled to an AB Sciex mass
spectrometer API 5500 Q-trap. The UPLC separation was carried out
on a reversed phase column (Acquity UPLC BEC C8, 1.7 μM, 2.1 mm
× 50 mm) using a mobile phase gradient with 0.1% formic acid and
acetonitrile as eluents. The detection of the drug was performed using
multiple reaction monitoring in the positive ionization mode. Plasma
samples were spiked with internal standard, and the analyte was
extracted from the matrix using tert-butyl methyl ether (tBME). The
organic phase was evaporated to dryness under a stream of nitrogen.
The residue was dissolved in acetonitrile/0.1% formic acid for LC−
MS/MS analysis. Feces samples were homogenized with 4 times their
volume ethanol/water (4:1). Aliquots of the aqueous ethanolic extracts
were further diluted with acetonitrile/0.1% formic acid, spiked with
internal standard, and directly injected into the system.
Prediction of Human Clearance. Allometric methods used for
clearance prediction to human were simple allometry (3-species),
allometry with (a) correction by fu, (b) with correction by fu and MLP
(maximum life span), (c) with correction by fu and BrW (brain
weight); in addition, in vitro to in vivo (iviv) scaling from liver
microsomes and hepatocytes was used for clearance prediction (for
compounds 6 and 109, iviv from hepatocytes of 0.53 and 0.215 L/h/
kg may be included in the mean calculation). For compound 6, the
clearance prediction ranged from 1.45 L/h/kg (simple allometry) to
0.485 L/h/kg (BrW). Allometry with correction for fu and MLP was
chosen because of the highest R2 value (0.9992) in the linear
regression plot; the mean of all methods gives a clearance prediction of
0.88 L/h/kg. For volume allometry, methods included 3-species
allometry with correction for fu and human−dog proportionality.
Values ranged between 0.7 and 1.0 L/kg; the selected method of
choice was allometry with correction by fu (Vss = 0.85 L/kg), which
represents roughly the mean of the values. For compound 109 the
corresponding values were as follows: clearance prediction; MLP =
0.511 L/h/kg, BrW = 0.343 L/h/kg. Allometry with correction for fu
and scaling from liver microsomes and hepatocytes was included; the
mean of all methods gave a clearance prediction of 0.36 L/h/kg. For
volume allometry, methods included 3 species allometry with
correction for and human−dog proportionality. Values ranged
between 1.3 and 1.5 L/kg; the mean of all methods gave a volume
prediction of 1.4 L/kg.
In Vitro Cell-Based Reporter Assays. 7dF3 Luciferase
Reporter Assay.27 7dF3 cells were seeded at 5000 per well in 50
μL of Dulbecco’s modified Eagle medium (DMEM) with 4 mM
supplemental L-glutamine in 384-well white tissue culture plates
(Corning 3570, USA). After incubating overnight at 37 °C/5% CO2,
compounds ranging in final concentration from 90 μM to 0.3 nM were
added in duplicate to the wells. After 2 h of further incubation as
above, β-oestradiol was added to a final concentration of 10 μM. The
cells were incubated for 24 h at 37 °C/5% CO2, and then 25 μL of
luciferase reagent (SteadyGlo, Promega,USA) was added and mixed.
After leaving the plate for 60 min at room temperature, luminescence
was read on a plate luminescence reader (TopCount, PerkinElmer,
USA). Percentage inhibition for each compound concentration was
calculated using total counts (no compound) and low counts (no β-
oestradiol) as highs and lows, respectively. IC50 was subsequently
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determined using a curve-fitting software package in Excel (Excelfit,
IDBS, U.K.). Data are reported as average values of at least two
determinations with standard deviations unless otherwise noted.
In Vitro Biochemical Assays. CDK8 Lanthascreen Binding
Assay. The assay format was a FRET based Lanthascreen binding
competition assay. A dye-labeled ATP competitive tracer served as a
FRET acceptor upon binding to CDK8. This CDK8 was His-tagged.
The FRET donor was a strepavidin-Eu-chelate bound to a biotinylated
anti-His antibody. When the tracer is competed by an inhibitor, the
respective FRET signal is affected. The CDK8 used for this assay was a
protein coexpressed with CycC. The assay procedure for assays in the
384-well plate format (Greiner PS, white, medium binding no.
784075) was the following: 2 μL of CDK8/biotin-anti-His Ab/SA-Eu
mix in assay buffer was pipetted into the wells of the microplates. Then
1 μL compounds in 20 mM Hepes buffer/5% DMSO was added. The
plates were shaken for 30 s and incubated for 20 min at rt. Then 2 μL
of Alexa647 tracer in assay buffer was added. The plates were shaken
for 30 s and incubated for 60 min at rt in the dark. Finally the plates
were read out on a PerkinElmer Envision 2104 (mode LANCE/TRF,
excitation 340 nm, emissions at 615 and 615 nm). For evaluation the
emission ratios (615 nm/655 nm) were calculated. These were
normalized to data from control wells containing vehicle only or 6 at
30 uM. The assay buffer was 50 mM Hepes, pH 7.5 (Merck no.
1.10110), 10 mM MgCl2 (Merck no. 1.05833), 1 mM EGTA (Merck
no. 1.08435), 0.01% Brij-35 (Pierce no. 28316). The final
concentrations of the reaction components in 5 μL total assay volume
were 1% DMSO (Merck no. 1.02950), 5 nM CDK8 (CDK8/CycC
Invitrogen no. PV4402), 2 nM biotin-a-His Ab (Invitrogen no.
PV6089), 2 nM SA-europium (Invitrogen no. PV5899), 10 nM
Alexa647 tracer (Invitrogen no. PV5592). Data are reported as average
values of at least two determinations with standard deviations unless
otherwise noted.
Reporter Displacement Assay for CDK8 and CDK19.
Interaction of compounds with human CDK8(aa1-464)/cyclin C-
(aa1-283) and human CDK19(aa1-502)/cyclin C(aa1-283) was
analyzed using the reporter displacement assay provided by Proteros
Biostructures GmbH.42 In brief, the reporter displacement assay is
based on reporter probes that are designed to bind to the site of
interest of the target protein. The proximity between reporter and
protein results in the emission of an optical signal. Compounds that
bind to the same site as the reporter probe displace the probe, causing
signal diminution. Reporter displacement is measured over time after
addition of compounds at various concentrations. For IC50
determination, percent probe displacement values are calculated for
the last time point at which the system has reached equilibrium. For
each compound concentration, percent probe displacement values are
calculated and plotted against the compound concentration. IC50-like
values (corresponding to 50% probe displacement) are calculated
using standard fitting algorithms. Data are reported as average values
of at least two determinations with standard deviations unless
otherwise noted.
Human Tumor Xenograft Efficacy Study. All animal procedures
were conducted in accordance with NCRI guidelines43 and U.K.
Home Office regulations. Female athymic nude mice Crl:Nu(NCr)-
Foxn1nu supplied by Charles River Laboratories were acclimatized for 1
week prior to use. The human colorectal adenocarcinoma cell line,
SW620 (ATCC, no. CCL-227), was expanded in culture, and 5 million
cells were injected sc into the right flanks of animals (n = 12 per
group) under isofluorothane anesthesia. Tumors were established for 7
days when dosing commenced (day 0) and continued for 16 days.
Compound 109 was prepared 24 h prior to administration to mice.
The compound was weighed into a glass 30 mL universal tube, and
Methocel solution (0.5% Methocel, 0.25% Tween 20 in sterile
phosphate buffered saline) was added to provide a final concentration
of 3 mg/mL 109. The preparation was agitated at room temperature
by magnetic stirrer to bring it into a fine suspension before use.
Animals were dosed orally by gavage every 24 h at 0.1 mL per 10 g
body weight. Tumors were measured three times weekly by Vernier
calipers and body weights recorded. At the end of the study, animals
were culled at intervals: 3 control and 3 treated at 1, 2, 6, and 24 h
after the final dose. Heparinized blood was collected by cardiac
puncture, spun, and plasma snap frozen for analysis of compound
exposure. Tumors were excised, weighed and samples snap frozen for
compound quantification and PD analyses. The 30 mg/kg q.d.
schedule was well tolerated with no significant body weight loss.
Tumor growth was significantly inhibited (T/C = 45.8; P = 0.0241
final tumor weights).
Pharmacokinetic Analysis. Plasma and tumor homogenates were
measured by LC−MS/MS on a Water TQS following a separation on
a Waters Acquity BEH C18 column (50 mm × 2.1 mm; 1.7 μm) with
conditions of 0.1% formic acid (mobile phase A) and methanol
(mobile phase B). The column was equilibrated at initial condition of
95% A and 5% B, linear gradient over 3 min to 100% B, held over 1
min, followed by linear gradient back to 5% B over 0.1 min, at 0.6 mL/
min flow rate. Detection was achieved in positive electrospray
ionization mode by multiple reaction monitoring, 412.17 > 376.40
at 33 eV for compound 109, and 299.19 > 91.24 at 33 eV, 299.19 >
177.29 at 26 eV for the internal standard olomoucine. Samples were
quantified by external standard calibration (8-point calibration ranging
from 2 nM to 50 000 nM). Quality controls were included at 25, 250,
2500, and 7500 nM in duplicate at the beginning and the end of the
analytical run.
Tumor Xenograft Processing and Western Blotting. Tumors
were excised, immediately snap-frozen in liquid nitrogen, and stored at
−80 °C until use. Samples were transferred to MK28 reinforced
homogenizing tubes with metal beads (Stretton Scientific), and CDK
lysis buffer (50 mM Tris-HCl, pH7.4, 1 mM EDTA, 1% Triton X-100
(v/v), 150 mM NaCl, 1 mM activated sodium orthovanandate, 1 mM
PMSF, protease cocktail (Sigma P8340 1:100), and phosphatase
inhibitors (Sigma P5726 and P0044 1:50 dilution) were added
immediately. The samples were ground using a Precellys 24 at 6000
rpm, 2 × 20 s (Stretton Scientific) and lysates frozen at −80 °C until
use. For analysis, samples were debanked and sonicated for 3 min, on
ice for 10 min. Tubes were spun at 14 000 rpm at 4 °C for 10 min, and
supernatants were collected, aliquoted, and frozen at −80 °C until use.
Tumor lysates were diluted 1:5 in lysis buffer and the concentrations
determined using a Direct Detect spectrometer (Merck Millipore).
Samples were aliquoted, then boiled in electrophoresis sample
buffer and loaded on SDS-4-12% PAGE gels. After transfer to PVDF
membranes, blots were blocked at room temperature for 1 h in
blocking buffer (5% dry milk in TNT: 1 M Tris-HCL, pH 8, 5 M
NaCl, 0.1% Tween 20) and then incubated at 4 °C overnight with the
appropriate antibody (Table 11). After washing with TNT, blots were
incubated with HRP-conjugated secondary antibodies in blocking
buffer at room temperature for 1 h, and bands were visualized using
the enhanced chemoluminescence (ECL prime) method.
Table 11. Antibodies Used in Western Blottinga
antibody name source catalogue no. dilution type
rabbit anti-Stat1 Santa Cruz sc-346 1:1000 primary
rabbit anti phospho-Stat1Ser727 CST 8826 1:2000 primary
mouse anti GAPDH Abcam Ab-8245 1:10000 loading control
α-mouse IgG HRP-linked CST 7076 1:10000 secondary
anti-rabbit IgG HRP-linked CST 7074 1:2500 secondary
aMembranes were cut and incubated at the same time for phospho-StatSER727 (84, 91 kDa), total Stat1 (84, 91 kDa), and GAPDH (37 kDa).
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Caco-2 data for compounds 6, 17−25, 41, 42, 44−49,
51, 54, 61, 63, 72, 85−95 (Table S1), CEREP profile of
109 (Tables S2 and S3), kinase profile of 109 (Table
S4), CYP450 inhibition for 109 (Table S5), plasma and
tumor concentration (Table S6), correlation of 7dF3 and
LS174T cell-based potency (Figure S1), analyses of
phospho-STAT1SER727 (Figure S2), total plasma and
tumor concentration (Figure S3), thermodynamic and
kinetic solubility protocols, preparation of compounds
9−13, 15, 17−22, 24, 26, 28−35, 40, 41, 43−53, 55, 56,
60, 62, 65, 67, 69−71, 76, 78, 79, 83−85, 87−91, 93,
94, 96, 103−108, 110, 111, 1H NMR spectra for all final
compounds, and small molecule X-ray crystallographic
data analysis (including Fo − Fc omit maps at 2.5σ cutoff)
for compounds 25, 42, 54, and 109 (PDF)
Molecular formula strings (CSV)
Accession Codes
Atomic coordinates and structure factors for the crystal
structures of CDK8/cyclin C with compounds 25, 42, 54,
and 109 can be accessed using PDB codes 5FGK, 5HBE,
5HBH, and 5HBJ, respectively.
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